<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-165488
<TYPE>S-3
<PUBLIC-DOCUMENT-COUNT>5
<FILING-DATE>20090805
<DATE-OF-FILING-DATE-CHANGE>20090805
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ACADIA PHARMACEUTICALS INC
<CIK>0001070494
<ASSIGNED-SIC>2834
<IRS-NUMBER>061376651
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>S-3
<ACT>33
<FILE-NUMBER>333-161059
<FILM-NUMBER>09988687
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>3911 SORRENTO VALLEY BLVD
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121
<PHONE>858-558-2871
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>3911 SORRENTO VALLEY BLVD
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ds3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<HTML><HEAD>
<TITLE>Form S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>As filed with the Securities and Exchange Commission on August&nbsp;5, 2009 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P
STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>FORM S-3 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>REGISTRATION STATEMENT
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>UNDER </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>ACADIA PHARMACEUTICALS INC.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of Registrant as specified in its charter) </B></FONT></P> <P
STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>06-1376651</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>3911 Sorrento Valley Boulevard, San Diego, CA 92121 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(858)&nbsp;558-2871 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address,
including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Uli Hacksell, Ph.D.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>ACADIA Pharmaceuticals Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>3911 Sorrento Valley Boulevard, San Diego, CA 92121 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(858)&nbsp;558-2871 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Name, address,
including zip code, and telephone number, including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B><I>Copies to:
</I></B></FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Glenn F. Baity</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Vice President and General Counsel</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ACADIA Pharmaceuticals Inc.</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>3911 Sorrento Valley Boulevard</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>San
Diego, CA 92121</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(858) 558-2871</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>D. Bradley Peck</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>J. Patrick Loofbourrow</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Cooley Godward Kronish LLP</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>4401 Eastgate Mall</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>San Diego, CA
92121-1909</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(858) 550-6000</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Approximate date of
commencement of proposed sale to the public: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">From time to time after the effective date of this Registration Statement, as determined by
Registrant. </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="1">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans,
please check the following box:&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="1">If any of the securities being registered on this Form are
to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&nbsp;&nbsp;<FONT
FACE="WINGDINGS">&#254;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="1">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the
Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT> </FONT></P> <P
STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering:&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman"
SIZE="1">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the
following box:&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="1">If this Form is a post-effective amendment to a registration statement filed
pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box:&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="1">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. </FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">Large accelerated filer&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">Accelerated filer&nbsp;&nbsp; <FONT FACE="WINGDINGS">&#254;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">Non-Accelerated filer&nbsp;&nbsp; <FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">Smaller reporting company&nbsp;&nbsp; <FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="1">(Do not check if a smaller reporting company)</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>CALCULATION OF REGISTRATION
FEE </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Title of Each Class&nbsp;of Securities to Be<BR>Registered</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Number of</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Shares to Be</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Registered</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Proposed&nbsp;Maximum</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Offering Price</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Per
Share(2)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Proposed&nbsp;Maximum</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Aggregate</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Offering&nbsp;Price(2)</B>
</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Amount of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Registration Fee</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="1">Common Stock, $0.0001 par value(1)</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">7,000,000</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">$4.17</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">$29,190,000</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">$1,629</FONT></TD></TR>
</TABLE> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">Pursuant to Rule&nbsp;416 under the Securities Act of 1933, as amended, or the Securities Act, the shares being registered hereunder include such indeterminate number of shares of
common stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. </FONT></TD></TR></TABLE> <P
STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule&nbsp;457(c)&nbsp;under the Securities Act, based upon the average of the high and
low prices for the common stock on July&nbsp;31, 2009, as reported by the Nasdaq Global Market. </FONT></TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="1"><B>The Registrant hereby
amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section&nbsp;8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="ARIAL" SIZE="2" COLOR="#de1a1e"><B>The information in this prospectus is not complete and may be changed. We may not sell the securities under this
prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where
the offer or sale is not permitted. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"
COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED AUGUST 5, 2009 </B></FONT></P> <P STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROSPECTUS </B></FONT></P> <P
STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g96979g88r93.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P> <P STYLE="font-size:30px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:30px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We may from time to time sell
up to 7,000,000 shares of our common stock, $0.0001 par value per share. You should read this prospectus and any supplement carefully before you invest. </FONT></P> <P STYLE="margin-top:30px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Our common stock is listed on The Nasdaq Global Market under the symbol &#147;ACAD&#148;. On August&nbsp;5, 2009, the last reported sale price for our common stock was $4.74. You are encouraged to obtain current
market quotations for shares of our common stock. </FONT></P> <P STYLE="margin-top:30px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our principal executive offices are located at 3911 Sorrento Valley Boulevard, San
Diego, California 92121, and our telephone number at that address is (858)&nbsp;558-2871. </FONT></P> <P STYLE="font-size:30px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Investing in our common stock
involves a high degree of risk. See &#147;<A HREF="#toc96979_2">Risk Factors</A>&#148; on page 1. </B></FONT></P> <P STYLE="margin-top:30px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P> <P
STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>The date of this Prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2009. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_1">ACADIA PHARMACEUTICALS INC.</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_3">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_4">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_5">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_6">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_7">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><A HREF="#toc96979_8">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ABOUT THIS PROSPECTUS </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">You should rely only on the information contained or incorporated by reference in this prospectus and any related prospectus supplement. We have not
authorized anyone to provide you with different information. No one is making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in
this prospectus and any prospectus supplement is accurate only as of the date on the front of this prospectus or the prospectus supplement, as applicable, and that any information we have incorporated by reference in this prospectus or any
prospectus supplement is accurate only as of the date given in the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any sale of our common stock. Our business,
financial condition, results of operations and prospects may have changed since that date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">References in this prospectus to
&#147;ACADIA,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to ACADIA Pharmaceuticals Inc., together with our wholly-owned subsidiaries, ACADIA Pharmaceuticals AB and ACADIA Pharmaceuticals A/S. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">&#147;ACADIA&#148; is our trademark. This prospectus also includes trademarks and trade names owned by other parties, and these trademarks and trade
names are the property of their respective owners. Use or display by us of other parties&#146; trademarks, trade dress or products in this prospectus is not intended to, and does not imply a relationship with, or endorsements or sponsorship of, us
by the trademark or trade dress owners. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_1"></A>ACADIA PHARMACEUTICALS INC. </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We are a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system
disorders. We currently are developing a portfolio consisting of our five most advanced product candidates including pimavanserin, which is in Phase III development for Parkinson&#146;s disease psychosis in collaboration with Biovail Laboratories
International SRL, a subsidiary of Biovail Corporation. In addition to pimavanserin, we have a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, each in collaboration with Allergan, as well as two
programs in IND-track development. All of the product candidates in our pipeline emanate from discoveries made using our proprietary drug discovery platform. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">We were incorporated in Delaware in January 1997. Our website address is www.acadia-pharm.com. The information contained in, or that can be accessed through, our website is not part of this prospectus. </FONT></P> <P
STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_2"></A>RISK FACTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">An investment in our common stock is risky.&nbsp;Prior to making a decision about investing in our common stock, you should carefully consider the specific risks discussed under &#147;Risk Factors&#148; in any applicable prospectus
supplement and in our filings with the Securities and Exchange Commission, or SEC, incorporated by reference in this prospectus, together with all of the other information contained in this prospectus and any applicable prospectus supplement or
incorporated by reference in this prospectus.&nbsp;The risks and uncertainties described in any applicable prospectus supplement and in our SEC filings are not the only ones facing us.&nbsp;Additional risks and uncertainties not presently known to
us, or that we currently see as immaterial, may also harm our business.&nbsp;If any of the risks or uncertainties described in any applicable prospectus supplement or our SEC filings or any such additional risks and uncertainties actually occur, our
business, results of operations and financial condition could be materially and adversely affected.&nbsp;In that case, the trading price of our common stock could decline, and you might lose all or part of your investment. </FONT></P> <P
STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_3"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">This prospectus contains, and the documents incorporated by reference herein and any prospectus supplement hereto may contain, forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of
1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our future financial performance and involve known and unknown
risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
Forward-looking statements may include, but are not limited to statements about: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the progress or timing of clinical trials involving our drug candidates; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the benefits to be derived from our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the progress of our research and development programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the benefits to be derived from relationships with our collaborators; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the receipt of regulatory clearances and approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">our estimates of future payments, revenues and profitability; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">our estimates regarding our capital requirements and our need for additional financing. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In some cases, you can identify forward-looking statements by terms such as &#147;may&#148;,
&#147;will&#148;, &#147;should&#148;, &#147;could&#148;, &#147;would&#148;, &#147;expects&#148;, &#147;plans&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;projects&#148;, &#147;predicts&#148;,
&#147;potential&#148; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading &#147;Risk Factors&#148; in our SEC filings, and may provide additional information in any
applicable prospectus supplement. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">You should read this prospectus, the registration statement of which this prospectus is a part, the documents incorporated by reference herein, and any
applicable prospectus supplement completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary
statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">You should rely only on the information contained, or incorporated by reference, in this prospectus and any applicable
prospectus supplement. We have not authorized anyone to provide you with different information. The common stock offered under this prospectus is not being offered in any state where the offer is not permitted. You should not assume that the
information provided by this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of this prospectus or the prospectus supplement, as applicable, or that any information incorporated by reference in
this prospectus or in any prospectus supplement is accurate as of any date other than the date given in the document incorporated by reference. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to
reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. </FONT></P> <P
STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_4"></A>USE OF PROCEEDS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">We will retain broad discretion over the use of the net proceeds from the sale of our common stock offered under this prospectus. Unless we indicate otherwise in the applicable prospectus supplement, we anticipate that any net proceeds will
be used for working capital and general corporate purposes. We will set forth in the applicable prospectus supplement our intended use for the net proceeds received from the sale of any common stock sold pursuant to that prospectus supplement.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_5"></A>PLAN OF DISTRIBUTION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">We may sell the common stock to one or more underwriters for public offering and sale by them and may also sell the common stock to investors directly or through agents. We will name any underwriter or agent involved
in the offer and sale of common stock in the applicable prospectus supplement. We have reserved the right to sell or exchange our common stock directly to investors on our own behalf in those jurisdictions where we are authorized to do so.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We may distribute the common stock from time to time in one or more transactions: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">at a fixed price or prices, which may be changed; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">at market prices prevailing at the time of sale; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">at prices related to such prevailing market prices; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">at negotiated prices. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We may also, from time to time, authorize dealers, acting as our agents, to offer and sell the common
stock upon the terms and conditions set forth in the applicable prospectus supplement. We, or the purchasers of the common stock for whom the underwriters may act as agents, may compensate underwriters in the form of underwriting discounts or
commissions, in connection with the sale of the common stock. Underwriters may sell the common stock to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or
commissions from the purchasers for whom they may act as agent. Unless otherwise indicated in the applicable prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase the common stock as a principal, and may
then resell the common stock at varying prices to be determined by the dealer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We will describe in the applicable prospectus supplement
any compensation we pay to underwriters or agents in connection with the offering of our common stock, and any discounts, concessions or commissions allowed by underwriters to participating dealers. Dealers and agents participating in the
distribution of the common stock may be deemed to be underwriters, and any discounts and commissions received by them and any profit realized by them on resale of the common stock may be deemed to be underwriting discounts and commissions. We may
enter into agreements to indemnify underwriters, dealers and agents against certain civil liabilities, including liabilities under the Securities Act and to reimburse these persons for certain expenses. We may grant underwriters who participate in
the distribution of the common stock we are offering under this prospectus an option to purchase additional shares to cover over-allotments, if any, in connection with the distribution. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To facilitate the offering of our common stock, certain persons participating in the offering may engage in transactions that stabilize, maintain, or
otherwise affect the price of the common stock. This may include over- allotments or short sales of the common stock, which involve the sale by persons participating in the offering of more common stock than we sold to them. In these circumstances,
these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the common stock by
bidding for or purchasing common stock in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if the common stock sold by them is repurchased in connection with
stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the common stock at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any
time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Certain underwriters, dealers or agents and their associates may engage in transactions with and perform services for us in the
ordinary course of our business. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_6"></A>LEGAL MATTERS </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Cooley Godward Kronish LLP, San Diego, California, has given its opinion to us as to certain legal matters relating to the validity of the shares of our
common stock to be offered by this prospectus. Any underwriters will be advised about the other issues relating to any offering by their own legal counsel. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_7"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The financial statements and management&#146;s assessment of the
effectiveness of internal control over financial reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended
December&nbsp;31, 2008 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><A NAME="toc96979_8"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We are a reporting company and we file annual, quarterly and current reports, proxy statements and other information with the SEC. We have filed with the
SEC a registration statement under the Securities Act with respect to the common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement or the exhibits which are part of the registration statement. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and the exhibits filed as part of the
registration statement. You may read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our
SEC filings are also available to the public from the SEC&#146;s website at www.sec.gov. We maintain a website at www.acadia-pharm.com. The information contained in, or that can be accessed through, our website is not part of this prospectus.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we can disclose important
information to you by referring to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We
incorporate by reference the following documents we filed with the SEC pursuant to Section&nbsp;13 of the Exchange Act: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2008 (including information specifically incorporated by reference into our Form 10-K from
our Proxy Statement for our 2009 Annual Meeting of Stockholders); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, and June&nbsp;30, 2009; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Current Reports on Form 8-K filed on March&nbsp;25,&nbsp;April&nbsp;27,&nbsp;May&nbsp;7, and July&nbsp;28, 2009; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Description of our common stock contained in our registration statement on Form 8-A dated May&nbsp;19, 2004; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">All documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus and before the last
offering of common stock under this prospectus (excluding any portion of such documents which are furnished and not filed with the SEC). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">You may access our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, Proxy Statement, and amendments to those documents filed or furnished pursuant to Section&nbsp;13(a) or 15(d)
of the Exchange Act with the SEC free of charge at the SEC&#146;s website or our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website does not constitute
incorporation by reference of the information contained in our website. We do not consider information contained on, or that can be accessed through, our website to be part of this prospectus or the related registration statement. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">You may request a copy of our SEC filings at no cost, by telephoning or writing us at the following address: </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Investor Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">ACADIA Pharmaceuticals
Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3911 Sorrento Valley Boulevard </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">San Diego, CA 92121 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(858) 558-2871 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;14. Other Expenses of Issuance and Distribution </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth the costs and expenses, payable by us in connection with the offering of common stock being registered. All amounts are
estimates except the registration fee. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Amount&nbsp;to<BR>Be Paid</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,629</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,000</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,000</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Transfer agent fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,500</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,000</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Miscellaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,871</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">55,000</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;15. Indemnification of Directors and Officers </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Section&nbsp;102 of the Delaware General Corporation Law allows a corporation to eliminate the personal liability of directors of a corporation to the
corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law,
authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the
request of the corporation in related capacities against amounts paid and expenses incurred in connection with an action or proceeding to which he is or is threatened to be made a party by reason of such position, if such person shall have acted in
good faith and in a manner he reasonably believed to be in or not opposed to the best interest of the corporation, and, in any criminal proceeding, if such person had no reasonable cause to believe his conduct was unlawful; provided that, in the
case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the
adjudicating court determines that such indemnification is proper under the circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our amended and restated certificate of
incorporation and bylaws include provisions that indemnify our directors and officers for actions taken in such capacity, if the actions were taken in good faith and in a manner reasonably believed to be in our best interests and, in a criminal
proceeding, the director or officer had no reasonable cause to believe that his or her conduct was unlawful. A director or officer who is successful in defending a claim will be indemnified for all expenses incurred in connection with his or her
defense. We have entered into indemnification agreements with our officers and directors that require us to indemnify such persons against any and all expenses (including attorneys&#146; fees), witness fees, damages, judgments, fines, settlements
and other amounts incurred in connection with any action, suit or proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was or at any time becomes a director, an officer
or an employee of ACADIA or any of our affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal proceeding,
had no reasonable cause to believe his or her conduct was unlawful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We maintain directors and officers insurance providing indemnification
for certain of our directors, officers, affiliates, partners and employees for certain liabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">II-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;16. Exhibits </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to Registration Statement No. 333-113137).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.5 to Registration Statement No. 333-113137).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of common stock certificate of Registrant (incorporated by reference to Exhibit 4.1 to Registration Statement No. 333-52492).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">4.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant to Purchase Preferred Stock issued to GATX Ventures on May 31, 2002 (incorporated by reference to Exhibit 4.3 to Registration Statement No. 333-113137).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">4.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant to Purchase Common Stock issued to purchasers in a private placement on April&nbsp;20, 2005 (incorporated by reference to Exhibit 4.3 to Registration Statement No. 333-124753).
</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">4.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Warrant to Purchase Common Stock issued to Kingsbridge Capital Limited on August 4, 2008 (incorporated by reference to Exhibit 4.4 to Registrant&#146;s Quarterly Report on Form 10-Q, filed
August 7, 2008).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Opinion of Cooley Godward Kronish LLP.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">23.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Counsel (included in Exhibit 5.1).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Power of Attorney (included on signature page).</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;17. Undertakings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">A. The undersigned Registrant hereby undertakes: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(1) To file, during any period in which offers or sales
are being made, a post-effective amendment to this registration statement: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) To include any prospectus required by section 10(a)(3) of
the Securities Act of 1933, as amended, or the Securities Act; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Securities and Exchange Commission, or the Commission, pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii) To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">provided, however, that subparagraphs (i), (ii)&nbsp;and (iii)&nbsp;above do not apply if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference in the
registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">II-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of
the offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) If the Registrant is relying on Rule 430B: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(a) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes
of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) If the Registrant is subject to Rule 430C, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses field in reliance on Rule 430A, shall be deemed to be part of
and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">B. For the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities,
the undersigned Registrant hereby undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the
securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(1) any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">II-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(2) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
Registrant or used or referred to by the undersigned Registrant; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(3) the portion of any other free writing prospectus relating to the
offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(4) any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">C. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#146;s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act
(and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">D. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to provisions described in Item&nbsp;15 above
or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">II-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly
caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August&nbsp;5, 2009.</FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ACADIA PHARMACEUTICALS INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;U<SMALL>LI</SMALL>
H<SMALL>ACKSELL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B></B><B>Uli Hacksell<BR>President and Chief Executive Officer</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and
appoints Uli Hacksell and Thomas H. Aasen, and each of them, as his or her true and lawful attorneys in fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all
capacities, to sign any and all amendments (including post effective amendments, exhibits thereto and other documents in connection therewith) to this registration statement and any subsequent registration statement filed by the Registrant pursuant
to Rule 462(b) of the Securities Act of 1933, as amended, which relates to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys in fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she
might or could do in person, hereby ratifying and confirming all that said attorneys in fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;U<SMALL>LI</SMALL>
H<SMALL>ACKSELL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Uli Hacksell</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">President, Chief Executive Officer and Director (Principal Executive Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;T<SMALL>HOMAS</SMALL> H.
A<SMALL>ASEN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Thomas H. Aasen</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Vice President, Chief Financial Officer, Secretary and Treasurer (Principal Financial Officer and Principal Accounting
Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;L<SMALL>ESLIE</SMALL>
I<SMALL>VERSEN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Leslie Iversen</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;M<SMALL>ICHAEL</SMALL>
B<SMALL>ORER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Michael Borer</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;L<SMALL>AURA</SMALL> A.
B<SMALL>REGE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Laura A. Brege</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;M<SMALL>ARY</SMALL> A<SMALL>NN</SMALL>
G<SMALL>RAY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Mary Ann Gray</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;L<SMALL>ESTER</SMALL>
K<SMALL>APLAN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Lester Kaplan</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>

<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;T<SMALL>ORSTEN</SMALL>
R<SMALL>ASMUSSEN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Torsten Rasmussen</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;A<SMALL>LAN</SMALL>
W<SMALL>ALTON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Alan Walton</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 5, 2009</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to Registration Statement No. 333-113137).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.5 to Registration Statement No. 333-113137).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of common stock certificate of Registrant (incorporated by reference to Exhibit 4.1 to Registration Statement No. 333-52492).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant to Purchase Preferred Stock issued to GATX Ventures on May 31, 2002 (incorporated by reference to Exhibit 4.3 to Registration Statement No. 333-113137).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Warrant to Purchase Common Stock issued to purchasers in a private placement on April&nbsp;20, 2005 (incorporated by reference to Exhibit 4.3 to Registration Statement No. 333-124753).
</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Warrant to Purchase Common Stock issued to Kingsbridge Capital Limited on August 4, 2008 (incorporated by reference to Exhibit 4.4 to Registrant&#146;s Quarterly Report on Form 10-Q, filed
August 7, 2008).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Opinion of Cooley Godward Kronish LLP.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">23.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Counsel (included in Exhibit 5.1).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Power of Attorney (included on signature page).</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>dex51.htm
<DESCRIPTION>OPINION OF COOLEY GODWARD KRONISH LLP
<TEXT>
<HTML><HEAD>
<TITLE>Opinion of Cooley Godward Kronish LLP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 5.1 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g96979g18x21.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">D. Bradley Peck </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(858) 550-6012
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">bpeck@cooley.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">August&nbsp;5, 2009 </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">ACADIA Pharmaceuticals Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">3911 Sorrento Valley Boulevard </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">San Diego, CA 92121 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Ladies and Gentlemen: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We have acted as counsel to ACADIA Pharmaceuticals Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the Registration Statement on
Form S-3 (the &#147;<B><I>Registration Statement</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), relating to an aggregate of 7,000,000 shares (the &#147;<B><I>Shares</I></B>&#148;) of the
Company&#146;s common stock, par value $0.0001 per share (&#147;<B><I>Common Stock</I></B>&#148;). The Shares are being registered for offering and sale from time to time pursuant to Rule&nbsp;415 of the General Rules&nbsp;and Regulations
promulgated under the Securities Act (the &#147;<B><I>Securities Act Rules</I></B>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In connection with this opinion, we have examined and relied
upon the originals, or copies certified to our satisfaction, of such records, documents, certificates, opinions, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. As
to certain factual matters, we have relied upon certificates of the officers of the Company and have not sought to independently verify such matters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In
rendering this opinion, we have assumed the genuineness and authenticity of all signatures on original documents; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies;
the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents where authorization, execution and delivery are prerequisites to the effectiveness of such documents.
We have also assumed that, at the time of issuance and sale of the Shares, a sufficient number of shares of Common Stock is authorized and reserved or available for issuance and that the consideration for the issuance and sale of such Shares is not
less than the par value of the Common Stock, and that, prior to any offering and sale of the Shares, the Company&#146;s board of directors (the &#147;<B><I>Board</I></B>&#148;), including any appropriate committee appointed thereby, will duly
authorize the terms of and the prices at which the Shares are to be issued and&nbsp;sold. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Our opinion herein is expressed solely with respect to the
federal laws of the United States and the Delaware General Corporation Law. We express no opinion as to whether the laws of any jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any
federal or state antifraud law, rule&nbsp;or regulation relating to securities, or to the sale or issuance thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On the basis of the foregoing and in
reliance thereon, and subject to the qualifications herein stated, we are of the opinion that, with respect to any offering of Shares, when (i)&nbsp;the Registration Statement, as finally amended, has become effective; (ii)&nbsp;an appropriate
prospectus supplement with respect to the Shares has been prepared, delivered and filed in compliance with the Securities Act and the applicable Securities Act Rules; (iii)&nbsp;if the Shares are to be sold pursuant to a purchase, underwriting or
similar agreement, such purchase, underwriting or similar agreement has been duly authorized, executed and delivered by the Company and the other parties thereto </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858)&nbsp;550-6000 F: (858)&nbsp;550-6420 WWW.COOLEY.COM
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g96979g18x21.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">and has become a valid and binding agreement of the Company; (iv)&nbsp;the Board, including any appropriate committee appointed
thereby, and appropriate officers of the Company have taken all necessary corporate action to approve the issuance and terms of the Shares and related matters; and (v)&nbsp;the terms of the Shares and of their issuance and sale have been duly
established in conformity with the operative certificate of incorporation and bylaws of the Company and the Delaware General Corporation Law so as not to violate any applicable law, the operative certificate of incorporation or bylaws of the Company
or result in a default under or breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, then the Shares,
when issued and sold in accordance with a duly authorized, executed and delivered purchase, underwriting or similar agreement, will be duly authorized, validly issued, fully paid and nonassessable. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption &#147;Legal Matters&#148;
in the prospectus included in the Registration Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Very truly yours, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>C<SMALL>OOLEY</SMALL> G<SMALL>ODWARD</SMALL> K<SMALL>RONISH</SMALL> <SMALL>LLP</SMALL> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;D. Bradley Peck</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Bradley Peck</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858)&nbsp;550-6000 F: (858)&nbsp;550-6420 WWW.COOLEY.COM
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>dex231.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML><HEAD>
<TITLE>Consent of Independent Registered Public Accounting Firm</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 23.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Consent of Independent Registered Public Accounting Firm </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We hereby consent to the incorporation by reference in this
Registration Statement on Form S-3 of our report dated March&nbsp;4, 2009 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in ACADIA Pharmaceuticals Inc.&#146;s Annual Report on
Form 10 K for the year ended December&nbsp;31, 2008. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">/s/&nbsp;PricewaterhouseCoopers LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">PricewaterhouseCoopers LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">San Diego, California </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">August&nbsp;5, 2009 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g96979g18x21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96979g18x21.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0RN4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````,@```(H````&`&<`,0`X
M`'@`,@`Q`````0`````````````````````````!``````````````"*````
M,@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"A(````!````<````"D`
M``%0```UT```"?8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``I`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T#K/7J>FEM%;#D9ED>G2V=)T:Y^W<[W.^@QOO>J`N^NE@]454U@ZB
MH[9_Z3_^_IOJW6W-ZIG]4M]U@L+*IUVAT_\`4T^G5_GKI4-T[.7T3JN5G&^C
M,H^SY6+M]1NH!#]VUP:[W-^@M/C4H=[Z<>NS*L``K87/?&NU@+US>%T_(^L>
M[J'4K7UXQ<1CX]9@``[2[NW^1N^G9_Q:7XJ_!Z@$$2-0G7+YW2LGH#/VATJY
MYJK(^T8]AEK@3MG\W=S_`%ZU>ZMUUU72\>_!$Y&?M&.")(W"=VW\YS9V?\8E
M:J[.R2!`)B>$ZYZKZGX]C!9U#(NORG:V/#])\&[P]SMO\I1P;<SHW5J^DY%K
MLC#R1^JV/^DT_N?]'9L_XO9L2M5=BSRB?^>.&),>@[2=.+ET"Y_*_P#%EA_\
M0[_J;T/K61D]0ZL.C4W_`&;'K9ORK)VDS^;RW=[7U_H_^%]_\VEW\TUMY/1@
M@R`9CE.N6R?JYA8])OZ7F.KRZAN83:WW0-6RW;MW*PTN^L?U=)=IF5$ZCVCU
M6:C_`+>J?_X(E:*>A263]6NI'.Z8P6&;\?\`16SR8^@\_P!=GTO^%]18'4B[
MZP_76CIK23@=)'J9(!T<\;7O8[][<_T*/_8E(RH#Q9,6+C,K/#&$3*4M]`__
MT.KQ<@=`ZYDX^5[,/,<;*[/S1)+F'^JS?Z-O_6[/H+J&O8]H>QP<UPD.!D$>
M,JAU!_1\JQO3LV'O<6[1M=#7.W>G^L,&RBVS:[T_TK++%AGH'0#9?4W-O972
M+++6D0TMJ.W(=78ZD57_`&=_LNV>MZ+_`.=0NE_!(ZT?L=O(R<;JN-G]/PWB
MRQM)8YX^ANL:]K&!_P"=MV^]5?JIGU68`P7?H\K%+FOJ=HZ"YSMVW^3NV/1N
MCCHF)2QN"2TY-GI38'BUUC6/R/3M9:UME3OL['VL8]E?Z/\`XQ5>H8OU:ZFP
MY[[0P^B[)=D5':357[7W/EKF.V1^YZB7CHK@EMPG[$WUHZC1C].LQ9W9&2-E
M=0U=!/N?'_4_\(L[JF'D8'2^D9+F[CTYS#>T=I++/_/E?IJUCX/U;Z/;5>YS
MK+K6FZNZP.LVL&T.O=Z5?HT,;ZK/T]NS_C%K'/Z?;E6=.<\.N$L?6YIVDEC;
M75;WM]&U_H6,L?2U^_TD/JKAD!\IK4[=MTV-E8^72V_'>+*W\.'_`%+OW7?R
M5S^=>SJGUDPL?%(L9@DV76-U`(+7.;N_DNKK9_;3Y_U;^KU+GV666XK?2?<^
MMCI;Z=6WUG0]EKMK/49[/^VUH=/_`&+TZX].Q!Z=Q<&N):\[G[?5%9R7M]-]
MOH_I/1]7Z"*A$[@$Z'HT\K_Q98?_`!#O^IO5'/Q.GM^M%C.JLW8F6T/J<XEK
M0^&5AQ>QS?HNK?7_`-=K6J[(Z#;ENZPZXA^#6-UAWAGIO]2MES6ENV^FS]+Z
M>15OJ5G/KZ3U`-Q,N'N-IIKY#A;Z;LDM8]OT7?9V^I^XA_%7#(;Q(T[-+*^K
MOU7PZ'9&1CAE;-2?4LU/9K?TGN<Y6OJ^>GNZ>+>GTOHIM>7%EA<3N$5N(<]U
MFYOL_,<LG$Z']6'.]076WUUN8T,MEK#ZSO1H->VJGU:;K/8RRMWH6+I,>RAS
M"RB-E)-6UH@-+/;LC^2B/HB0D-P?J\MU?)=]6.J7]18W=C9E;R&<`W#5K>?]
M+[_^+NN_<5GZB=+LQ.CG.R279G4W?:;GN^D6NEU6[^MO??\`\9>]4/K&7?6'
MZRXGU=J,XF&?M&>1XQ]#=_Q3_2_KY?\`P2[,`-`:T0!H`.`$T:R)Z#;]K//]
M7AC#]++4Y?[./\W'_"^=_]'N[;V5=0R`YK+&NRL5K@]Y807-8VI];0UWJ/\`
M5_,_1JEDN;]EN$C=]CZO\=+Z@[_-4>J_^+GIG_A=W_5/5?IO_+GUK_J-_P"H
ML3#U;<*]/>H_XW!_WC=SKVXMF?GD?T)^(XNYVDM]&_\`ZY]ERO\`IJNRFJFO
M,Z>VLO\`L[\?`V-(E[;[?ME];-Y:W^B9*ET?_P`09_XBW\KEH'_E&S_TY,_]
MLJT#_'^U=';ZQK_F>W_ZE<N^V^S%IW'T]F%?CYH@/<VNN^G$S75N:[9ZM%;+
MG_X9BO.+?VE:P'WGJM>T=],&ASX_JL2K^E=_Q74?_;IRJ]"_\5>9_P"$J/\`
MJ*$O[%'8^4ZK^_%O?6#<W-P;W$?9\867Y3".:F68NYV[\QN,\UYG_H,HG>>L
M;;7@8IS26@#W>NW&J=4U]A=_,OK]?_![_6KI_2?I%8Z[_-7?^$,S\E"CD_3?
M_P"G#'_ZC'1.Y\PQP^2/]R?_`$O^DY>"RF[I%%%D&NWI.#7:!SLL+ZW?YS=Z
ML4WE]V);;J]O4K&6QJ=]6!D46_\`3J>J?U?_`/6A_P#3D[_SXM'%_I;/_3M?
M_P"VV0EV^C)/>?\`A?\`0]37!#<9N/4X.!^PV8.2X2X8[\FOT*+V^W=]G=]#
MW_IJO^%]2Q7/VDSI/2>H9V4X/--]Q``VASR[;56ULN^F\L8L;ZL?S?5O_3K5
M_P"?ZD7ZV_\`(5O_`(?/_HQ(7TWI;+A_2^3C'%^]^CQ+?4?"R*<9O5LJ'9?6
M;76/>1KZ0;98S;^YZUOZ;_B?06[A9>9D6XLZM?C577PT!LV-LU!GU-WJ,9[%
M2ZA_R3T3_P`,8?Y$3ZI_\G,_JG_S]E)1V%;*YCY\G%7'T_=X->'A/]SA?__9
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`
M+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_
MVP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__`
M`!$(`#(`B@,!$0`"$0$#$0'_W0`$`!+_Q`#2```!!0$``P`````````````)
M``8'"`H%`@,$`0`!!`,!```````````````%``,$!@$"!P@0```&`0$%`P8)
M"P('``````$"`P0%!@<(`!$2$PD4-C<A,2(5-3@R8C-C-&1E%SDC4U15=196
M9F>W:$%184)2A"<86!$``0,"`08(!PD*"0T!`````0(#!``1!2$Q$C(S!D%1
M82(3-#4'<8&AL5)B%/"1P='A0L(C8X)#4U05918V-PCQ<J)SH[-$9'2RTN*#
MPR2$E+1%5856%__:``P#`0`"$0,1`#\`W+YMSOC73Y3'%WR7.IQ4>!Q;1D<@
M4KF;L$CP\1(R"C0.15\[$OI&'>5)$F\ZAR$`1V:>>;805N*L*>98<D+T&TW/
MF\-";-U*]4F6922)INTS!.0+-;E%>OJ_<;R]1*`%$II-Q67L%#1JR@&`>491
M3AW@`'-Y]A?Y0DNW,>/=/@)\V2BAPV.R![1(LKP@>?+7OA.J%F_&EH80&J/3
MVM5&3H2@LZAH2T5";10$Q0,_:0UP>2#::13(;?PI.4`,'F-Y=LC$7FU!,EBP
M\!'GI'#&G4Z460%'P@^:C3U^<C[/`0=EB%%%HJPQ$;.1BJJ1T%58^69(OV2B
MB"@`HBH=LX*(E,`"41W#Y=BZ5!24J&8B]!E)*5*2<X-JZ^V:Q2V5*ELJ5+94
MJ6RI4ME2H+=Q?OB]8''[$KUV5D:"1$S0'"P-3#]S=H4WF;@?E"/&`&\WG#?L
M'63^5FQ?);Z)HVV!^1W3;+?Z0HTFQB@E+94J6RI4ME2I;*E2V5*ELJ5?_]`]
M$I#R74*U[62K6&1?%PWB)W.1_98U<R:05*IROJI4&2I1`$G]]L8`=5S\LFT4
M`"B/(3``1"ITXI4?J47]X?&:/`B!!2I(^O78^,Y?(/+1\JQ5JW2H&-J]1@HN
MMUV';E:QD+"LD(^.9(%WCP(-FQ$TRF.<1,<VX3'.(F,(F$1$VE*4)"4)`2*!
MJ4I:BI:B5'A-<+(^,J)ERJ25)R)68RT5R4142692*`'4;*G2.D1]&/"\+N*E
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M3>=-.9:K(N`()$A*.\Y,E^;#(,BRVB<_N`\M(,09B5"/=#PX/DOYJ,50\E4[
M)&/H+)]7ED7-.L$($\UDES$0!JS(FH9\G(@8YB,W44JBJDZ(8P\E5(Y1'R;]
MBJ'$.(2XD\PB]"7&UMN*;6GG@T)6XZS=36I[)LYBW1'"-8JJUPX)2V3Y)A'+
M.'"0'7;GDEGT^B]@Z["O52F!FD5JXDW!4N:0Q-YDB"URY,AQ3<,`)'#[LEO+
M19$.-%;2[-5=1^;_``9;^2N;.0O5;P%&.<A.K]7LOPD,0TG/U9L9E;#'CVX&
M5<\V-=UFMV`6J">\RGJIT1<"%$?@@.VI3BC`Z0N!8&<9_@'DI!6%2#T804*X
M#F^/RT0/2%JQJ^JRA.9U@Q"NW.M+-H^[5,SCM(1SMTD<[.2C5S%(JZ@Y7DJ<
MDQR@HF=(Z9]XD`YY\62F2C2`LH9Q4"7$7%<T2;H.8^[AJ@MS_&+Q]^P4/[,V
MG:"OM9OP?1-$&^QG?#](5?/6/JQ@-*6.V\\JP1L%YM"[J,HE767,@W>O&J22
MC^7EE$A!RG!0A'*1EP2W*+*JI(E,GS!53G2Y*8S85:ZSD`^'P"A\.*J4YHWL
M@92?BY30]:O`]5S.L.WR4UR/#XRBIA/UI7ZQ('BZF<\>O^69@WA654FGQ6BR
M1@%(95<5SD$#&,(#Q;0`G$W@'`X$I.89O@/EH@582P2VILJ4,YS_``CR5(^G
M/6SFFFYK;:8]8\0@RM\H\:1-7NZ$?'QZSR7E%RDA6\N6&Y%?D8>=XP29OV2*
M7"MPD6*<3'42=CRWD.B/+'/X#YOX::D0F5,^TPU71PC/X>7)Q&G-KVS]J.TP
MY%QG?Z=8P?X2GW3!E8Z@YK=7<I!,Q#OM,K#^OE(4T^R;V>"#B1.#KF)+IK"0
MP%`I0S-?D1W&W$*^I.<6'GM?**U@1XTEMUM:?KAF-SYKVR&B;U&U0=YJU>N5
M9>DD:]:8:.GH9\3R`YC91HD\:*&+O$4U.2J`'(/I$.`E'R@.Q%*@M*5)/-(H
M:M*D*4A0YP-J"_UD>H#E?2G'X:Q#IKG$(W/.5YP\L=9*OPMJDHVG-'!82-:-
M82P1LO%J/+G9W?9VQC-U%-S!<"<)A`=JOO+B\B`(T:"Y:4X;Y@3;,!8@CG'S
M5Z9_=U[J,!WY=WBWAWRB%S=>"WH`%Q;25/$::E%;:D*LRV-)0T@+N)O>I>^Z
M3JA__50>Z1ZU\.<$>^'_``YX<>&/SWROQ]G?9=X/_)'J]]5O;>CJ:O+0/](N
MX[_X,=OZ&WG=D_A>L]9]3-R5_]'0/TRW2&.-6>H/%%H4!O:WJ-@AV7.WE,]D
M:1;7HS#9`3CQ',LT4.Y+Y^))$3>8-^P3#K-R'VE:_P`1H]B?UL6.\C4^,>X4
M?'8W0&ELJ5!5ZQ,I(*,M.E1.[7:5J>L-ZDI@2J&*U,]B$Z7'QSE8G%RS*L&5
MA>B03@.X%#</_-L'Q8FT=/S23\%&<'2+R5_.`%O+\5&,JM;@Z=6H&J5EDA&U
MZN1$?#0K%L!01;1L<U3:M$B"4``X@BF&\WG.81,(B(B.Q9*0A*4I%D@4(4HK
M4I:C=1-ZC;455:]=,$Y;KMI115A'E!LR[DR_#PM5HV*<R;"0(8X"":\<_9I+
MIF\Y3I@(;-OI2MEU*LVB:<CJ4A]I2<^D*"MIIN]LBNE]JD"/<.R>H[1*P<.Y
M*H?>TBK<RH3&QLVHAO%!))M,NEAX=P`9R8WD'>.PAA:AALFW`;#QV^.C4EM!
MQ.+<9"`3XKV\U7^Z7-4KL!I(J4S#E;GE;E/VZ;L[E,J8N#2;&POZZT:+JEWJ
M"1I#PS<2$,.XO,,8``3COG8:`(J2,Y)O[]0,44HRU@Y@!;WKT1+:?0Z@7:9&
MZ.-^J1FVAT9H5*GS3.ZM9-@SW]@B4!0A+>50J*9N2B6.L1>Q)>3\D5P*8;N+
M8-'^KQ)YM&J;_'YZ-R;N88RXX>>+6Y<X\U.*Y_C%X^_8*']F;3ME?:S?@^B:
M3?8SOA^D*B#J:2-QL.LS"E/K\%'6=_&U^D#3:O-E3&#LEAGKK(F]52A'3V/:
MJL9EVQ;-7`"N@!T@X3'+Y#;:XAIJE,I`!L!8'-<D_)6^&:"8CZU*L+FYX0`!
MF\%S5DPRUU;```#3SB@`````!2(```/(```9>W``!L]TN)_BZ?=]U4?H<)_&
M%^7_`#*JSJ`PYU%]1T_3[5=L"U>%L=&(L2$F*7,U>'?F(=XWD&Y'CA[D:6.L
M$>];\QN).6*1U#B`CQ>2*^U/D*;4M@!2>*WQFI<=[#HR5I1()"N.Y^B*-'J+
MPHRU"X.MF,9H$&LK-0Z3N#?J@!B0MQC2%>PK_B3XA!NG))@DX`GE.U44('PM
MB[[(?94VK.1Y:"QWC'?0Z,P/DX:'ITN\[N8RJY!TWY-7+7[!AAU.34:2:639
MJ,*TE(.QM\2\%PH`I#4IX%5E##Y"(.]WD*EM`PY_10XPZ;%%SEXN'WJ)SXBW
MWXZXJ"M;Q"0$BY*CD2`!G*K@`<=#7T00[OJ:]5#+.M*RLWBV&,!2\:OC1D_1
M<$;&6B1<PV'HTB#@%D$'B+2+<6:00(?\C)J`/D*J7?5,*2<<Q^1B:Q_NS1!3
MXLB!Y-(\M>U.\V2WW*]QN`]W$)Q(WBQ1M29"DG+9=ERUY+$@E:8[9(RM_P`6
MM6.W0:\(U__2TQZ[=).38?);'5QIH1D#76(<L9>WUZO(&<3II6,3(U2M4#%H
MI']<D>1Y`0E&)2G47*`J<"H*+``J9%=#@E1MH,X^$?"*,0);1;,23LSFOFR\
M!XN2NIB?JZ8P>P[2,SA3[33+HS(+69?UF,2FJNY=M@X%ETVB\BA8HA5=4H[V
MID'0(F]$5S;M^R:Q1LI'3(*5\@R5J]A3H4>A4"C@N<OQ4W<Q]6&,G&9Z9IAH
M=KL5XG%#1458+%#I`DW<N0Y:*U<JD8ZE9:P29A-^13<%;$*H`"9-8-Y!U>Q,
M$:$9LE9XQ\%;LX40=.2M(;'+YSP59K5#IBLFJ+2Q0H=T8S;-%1K-9LL8M/F,
MU<.[.>LLD+779A4X`#-:<6`P'.<H`F\12$XE(!QVDR8RI,=`)^N`!\=LOOU%
MBRDQ9*U#8DD<>2^2JL8(ZEB>'ZY'X<U7T3(-?O=#;-J\,\TA$EG3Z-CT2(1R
MMEAY1]%R3:1(S(0HN6Y72;XH`MZ(G'?&:Q'HAT4EM06G)?XZE/8;TIZ:*XDH
M5EM?S<GFIM:@]>%BU81*^G;2?CJZR;J]E]56BPR\<V;2`P2JR)73:/:1TA(-
MX:)=@/"]D9!=$J3<3DY9>/F%U?FJE#H(J"=+/X/=PUEB"F*2_*<2-',.7X?`
M*(=@G2/7,9Z6'6GBQ+)2:ES@Y_[PY-F43).K';&!6DBZC.<4H\N$12;H,U#%
M*8P,TU!*4QA`)S,5+<;H%<(R^$U`>E*<DB0,X(MX!\=#)Q#F;)_3,MECPMF^
MD3MIPY-3KJ<J=MKB!#&.NNDB@M*5IQ(+-(J31?M&J(O8M5RV<,ERB<!],05'
MM/.X>M3+R"62<A'N]\43=9:Q)"7F%@/`6(/P\/CJQ.1.KAB9.O+,\-4N]W'(
M$H@#:OLYV$:Q4&UE'0@BW]8@SEW\O)*H*'`P-6B`]I,`)@NGQ<8/N8HUHV92
M5.'-DR5&;PIXJN\M*6QGR_)YZ='3MTR7^C/KUJ,S<B^9Y4RR1RFVAY,O+E8J
M#E9-&>EW\XV.',92T_*-T#$;#P':-VX%.`&5$B>\&.X@K?>VJO-6N(26UA$=
MC9(\IS9/!4.7/\8O'W["0_LS:=F%]K-^#Z)J0WV.[X?I"I=ZE.FF_9$9T7/&
M'VS]_D/$)N)U#PZ1UIY_#-I)";BI6OH(D.L\EZO+IJ+`V(!E%DES"F`G2*FH
M]B$=;@0\UM$^;Y*8PV2VVI;#VS7Y\V7D(IK8TZNF)5ZPU;9CJ%VJ]^C6O9YQ
M&MQ#*8@9*2:AREU(OM4Q'R4<JZ4()A;.4@*W,(DYZG#QCJWBC6B`ZE07PY*V
M=PET*^I4%(.;W6M3$KVIO4YK1U!U`VG!O8L4X6HT@FI8[),,FKIF]CEEFAYA
M6VHB9W!RDLY:$Y4=#(++'()A5,J4HJ+)-B1)EOI]GNEH9_E^`5NN-&AQUB00
MI]0R`<'@^$T;;8Q0:LJO7/CW6GG(<1>L7SXPEBU/UFT52PPL([*A-`FC&,JS
M=78,&O`Y-%W."FF[4Q@`PJO!<&W\8AM2MZG_`&-`#2[.O@BPSV&0GQWMRY:]
M0_NR;F)WJWJ.,8BS?",&*'KD<U3Q)+*;G)S"DN'B"4\8HU?3+TG%T>:1L=8W
ME6*+7(E@0/D'*RI"$!<;U:D6[AS$.%""<JHU*(2:1`&*82*"Q,H7=S!V.X%A
M_P"3<.996/KU<Y?\8\'W(L/%7-N^K?T]X7>!B^+L.E6#LGV>*+Y.A:)`6/YU
M96[Q@+"3JU?_`&,5R>O_T]L68M2L?B.<FH1/&>1LAC3L=?>UD-_2$Z<#6CX]
M-(3L>G-/$K5;JR^GWS@:M**IQ\0B_>G1CU-R?&9`BH^5B"8KBF^@6O0;TUD6
MLE%R+Y2+G(<@N<E7?=O<E[>&+%E*QN'#$F;[)'#W37>D:+:B@%IIQ+:1TK0+
MCI0@%Q.6P44P5J:E]-C">L4K?-+3G,J=)QRPRUE;(=<JN/3_`+A8Y>N;"FUG
M9M]8+15K59W!651E7HQT2C)O@9L5#`D)U$$EF9DB.VXL*A*<"$!:U`)YJ3?*
M;D$FP)L+FP\%2=VMS,0QMF)HX_%A2)<Q42*T\7M*1(2&[H26VG$-C2=:1TCJ
MFT::P+V"BGH+WC3MI<R18ZC4].+^OQ%1IF/;KDO,M$JV/!K5#K63+#=ZW7'E
MJ76M3/)[Z+0=4&07?KQT3(M8]H`+KF(GQF+ER7'AOK;3$5T:4I4I:0FR0HJ`
M)RZ5N:;D`@#/6<*W(Q+>#!HF)-XY%3,DR'V8\5PO!Z0Y&0RMQ+:@RJ.%$/MA
M"7'FU.*.BD$V!E;(>K?&^,8G*<Q:(VTI-\2YCQKA:>2;,XI5Q)3V48#%UC@9
MZ$34F$2N*PSC\J-NUK+"BNF>.?`5$X)$%1V1B+$9$A;B56;<2@YLI4$D$9<W
M/%_`:8P;N_QG'9&!1H+S!7/PZ3,02562B,N2VM"[(-G"J,K1`NDAQJZAI&S+
MS_F?3Q&4;/EURUB@F18;33::U3;$TD*74;3)3%AM%3QW<F+&BMYUX`.U$8W*
M$>FL"AVA@7!<I0,!-YFY4^*RU->>:*DL*"3D!N5!)`3<^L.*M\`W#QO&\2W0
MPJ#,9;D8RPZ\T5*6E+;;3LAE2GB$G1!5&<(L%<W1)M?(Z['D.D8$FL>XZQ#I
M_F+=(9,JU[O47!85CL25-FA6L>.*&VFI:14N-SQS%NEG#C)$<#5-!5PNMQ*"
M)2@7>.[TM$93#<>*7"XE2@$:(R)T;GG%/I"U1<&W4<QF'C6(XCC\6!&@R&&%
MJD"0J[LCI]!($=A]0L([FD5``9,]ZYT]K&JC!CB>5JN,\KY)C<K8HM>;$CTN
M/IH2-0QY2G%!:623L<':+K6I=_)QKK(K%,8V%1EI%4Z:Q4D%!(4#MKQ9H)CK
M:8<<0XVISFZ-TI3H@W!()(*@+"YSVHE$[MY[KV/QY^-P(3\">U"^N4]HO2'@
M^6TMK:9<2E*@PL](\6FP"G24F^2QK=:DY2I47+=DA;I1[?!Q\['%DHUM*1$S
M"R[%-\P<G823=1%1)TR<E-PJ)@(`;<(`.\-B*5MO-)<3932D@CE!%Q5&EPY>
M'3I.'RFRW-8=4VM)SI6E12H9.(@C)51,6Y(TR-$V5KQ;@R+KCQQ@^;SO/2-:
MH5"A92H5)E(JQL!#V1Y%O$EF<_?G,5+FAFZ*BS=P2"?&452!(O,',38B@E;,
M<[$N&P`L.`'E58V'JFKGB&XN-PGG8TW$&0H8HB`BZG/K75)"G%MW1E;8"FNF
M4;%)>:`2K2-GC5]8E2D(.U3M_P`=Y*PZWJV$7.HH27=*C3(3N(X]FX>RUD@W
M6-KO>V1G4.FDF#F/=J-'Y!<(B5$Q3\0;-8FVI+BGF%M!+72Y=$W1PD%)5E'"
M,^44[/[N<09D0(V$8Q"Q%;^*##OJ>F06Y:B`AM:9++!LNYT7$!;?-5=0(M7R
M%U*59K$YFN=UP/D.D7W!N,HK+DM4)V*QQ*9`L-$L+"ZEK;NI2M7N=@@UY*5=
M4*7C3,7,FT<-'3?@7*FDJDHHA/2$2G'8BT/-(T]$Z)44F]K$$C+HD6OD.>M%
M;@O.3-VHV&;QP9>'XG.5$1(1TZ66WVRSTB70ZRVX$I2^TX%I0I*T*)3<I4`]
M);5%0(RAY*R.C'6*6J^-=/=9U)NW<6E#KC8Z';(&_P!BBFM;YLPBFXFS1^.W
M7$5P9LVXG"'"L8#*"FZN>REE]\`EMMD.9.%)"B+<O-/DJ%'W&Q9_%<%P9;S3
M<V;B[N'`*TQT;[2V&UERR20C2D)MHA2N:JZ1DO$N;;AI_89#E&MPTRL,H&J4
M91Y[*F2STK%<A'XYA;_-O(>O/YY:W2\;:;&5#U<X>O48IK(J-&"0J"4RAB)'
MCR9D=MU251"M*$I*U639(4;`FY!.8DZ(-A4K`]RL0Q;#6):,;CQWY+C[<5A9
M>Z22N.@+<2@MMK0B^DE""ZM`4X=&X`*A-#G,V/<?Q64&$?5I&+B,)W&@T*7C
M(")@V#%9_D&,H$I#K5UD@_9MO5K)OD1F5SS2MCD,BMP$.`$%20N:RRF3]6=%
MI:4FUOGZ-K9<PTA?-F-#8NZ6)3E[OA$EK2Q*-(?;N5<U,=3Z5A?-/.)CKT='
M2!!3<C+:P"ZZ+9%9RY52;MVZ2BZZZQRI(HHI$%15554XE(FDF0HB8PB```;Q
MVFD@`DG(*JJ$*<4E"$DK4;`#*23F`'&:RF8(2'JN]6RUYX?%5EM-^EQ6&7IS
M5\0SB+D(VK2CQ''+7LCE(403O5O:/[&N@H4#=F*=$^_A`-N>Q!^D.\+DM0O"
M8(M?-8:HL?2-U$>$5[OWJ5_^#]P<#=9E0;WQQL+#I3D4%.I!D*N,OU#11'2H
M?.T5"M7&W0Z\'4ME2K__U-?.<+).5#*NIBSP=:I=Q"O:.<8SE@J]^E7T179N
MI15SU-/K+'.7#"#L)U%7T6@=$B2K?LZ@J<*AREWCL"FK6U*Q%Q+2%I3$05)5
M>Q2%/$C,;W&2UK<==?W6A1<1W>W'@RILF,7MY9*&W6$I4XAY;.&);4`I;=@E
M1!)"M(6ND$TW\T/4'%>U[21DD8]LYT#49_R>(I&[1NI5-5*QB%.()D!!J0W#
MQ;@``#_3;1PZ1QM5K`Q4'^0Y4G=YI297=*P%%;B=ZGTWX2>GPT>^<_CIE:I3
M%)&]3`@B`*+].O%+-L41W'5?O6VM1G'MT@\YG+E\LFFD4/2,H8H!Y1#93B+8
MW_@D?[>B6Y`N[W)D:HWOED\6B%8.5$\@2"3P6O?)35U=P"-QU%6C`Q&Q?_*^
M*ZYFI@@DB("_L&+\;:I:?.2;HQ!*"YXR66QV1+?Z0&*&\P;DP!C%F^GEKA<#
MB`OQH2Z"??Z.I_=U-5AFZ$'>HKRX?.<ADDZK<J3A;J$CBTD>WD\&7-E538:6
M]OF_`>';G"TJ8NA]5>L.\9.EZ377%?2FI^CXRCK[#Q,FDK:)F!@C-VD/B>LG
M/SG1``%"%)Q&X=[`<,N%%<#)6J3*4O1%KE*`H7RD#,A)R\=$',/_`$9WMWBP
MV1B;<5.`[N,QD/N!PH0_)4PM23T2'%W*Y<@<U)S$FPO7Q-[3FF6H&BZQ8M?,
M8;,E%T.ZK824CYZ!1M)I2WXCG=+5'NM83;IRK5LC-.[35G!&[GC<HE<$`#)*
M$..Y%V6J/A+D<A,I$9X$$7NI'1I4,O#=)X\M.^P[LQ\8[S(>.-*=W<E[S84M
M*D++6BU+1B3[+I.B24);=25)LDE).4$59&@,*56\B:3&]-DW+^@LNG[GYY!S
M<THV[;(5]Q:](4BC,2YVZ+9D1V_;+"X<`FFDB0YS`0A"`!0FL)8;=PT,JNQ[
M$X03P@EHW/!EO<U2\7=Q.;A&_P"O$F$HQ96]T%*T(!LEP-8JDH0"2JR2-%-R
M20!<DY:L3H[353TEZ>2*D,F;[F:&8I#D$ABHJ5MB=OZ`@42E%`Q=P;@W!NVG
M80+83!%OO2?-5.[QRE7>'O>4$$?E-[WPX0?+>AVZ+8Z<HF`-05+NSYG-3^0<
M"I9SIMF!MV5T]QW)TRSX_;8];<Q10[AIB9W4$%%0)PIE5LQ5A*"CHYCA<(TF
MH,UIT@K6STB3PZ)24Z/@04_RN6NQ=Y;T;%M\-S\3PUM3<2)B_L+S=[I3(2\U
M(+YR"RI27B!>Y(C%-[(`''D&-A4T]:PS9/M99V[5+IF+L\8MHR!:5BOCA6^8
M1L<H\?\`8NU2DC,6M#(E,=L9%P9V+=%JU8BF@@=RH*B2E?LN)>T.Z3J8',R`
M#HU()O;.3I)()O:P''3Z'H8WO[NA@>']#A<C?8&45+4XY[:Q-;2!I62E#1CO
M(<;2$A14IVZE!`M;;4(H0]NUD%*<AC%T.XL4,4I@$2D6N>J<$CB`"(@1443<
M(^8W".[S#L2G;7$O\(G_`"G:Y[N<",/[N;@V_2B3Y&<,O[UQ5:YSD1&$.IIC
ME!LLS0PYI*LN,(YHN83F;5:'-J^F<>MRG$I>))'&U@ARE'_4`W^3S;0W;)AX
MZP/O48I\0Z4I_DD5=(VG(WF[DL96H*.(X^W)41PNK_)*)!_YAMVK(YQG*[5+
MEDG-=5!*8/B*M8_JNJO&UBBR.ZM?\12"0VV,G(A-P19!6_XVB9IX_8'$AD'S
M<SB.7+Q*-UVTF6I#3CTQH7+2$AY)&12#E!'K)!)''E2>`BF[KQID_#L%W8GD
MM)Q&0^[A<EM1#L>6D]"I"[6(8D*0A#@!TD*"'DFR5H7%N98.[.YW67+15Z0B
M:FSU`:8"S-0/4V,BM-*%J&F8QU$[&J_1=Q8*$43+PD14W<O>`^D.Z--0\58L
MM+UF@\S=.C>^1KAX/$*L&[,K#6X?=I'?PHN3UX3BF@]TJDA`Z7$LG1@:*N'*
M2,_)3%ZW6KO_`-=-*$EC:K2_8<H:A0>T6'*T6`LC%T82)!D";(4BA%T"N8ER
M$6DJ`;RJO^(@\2?DQO5B/LF'F,VJS[W-^Y^=[^KXZF?NS[@?I=OVSC<Z-IX)
MA%GE7'-4_EZ!'$=%0Z4CB0`<AKL]+K3;,:.\$:>:+*,BQ-YSG'WK*^9FKADD
M$D6:5AJ^ZIU:=*N$.W,%*977239=N4Q2`_,Z,(#QCLL"B+PV/`9(LX^%K7DR
MYAHCC%@<W&337?AOA%[P]YM\,48<Z3#<*6Q%AD$Z.CIN!YP`'15TS@)2HB_1
MAOBJT,5D_*EDK.D)Y&2EF>6/)>-*S=KH$!7:LM!RIBS."E+=(VQ5_#K?N]")
M5NV3)B>KE&:G/6(5+><J10G)DRG&\)4A2ND<;"E6";'*WI:5QD%E*S6-ZIDC
M`=WX,[O(:?CL)A09SC#/2..A:.9.#*60E8Z1PN,LWZ0+&BE15D))O#L:KE-?
M_]713U5_$>O]\O`NP=Q>X?>9W[\?^)/YO[0]8;5#>+K"=;8G5S:QVWV7%RZ5
M>INX3L67U?M5O;[;9#L;\Z>E]GT5<;J#>*6-._ON_4_N'X,]ZY_W_P#_`!-_
M1OC^NMFL7ZS'UNKIU=3.=O\`9\7W52^Z+L+&.K=L/;?K>R1V%^=/2_X:GKJR
M_$`@O:/AQIC[U>[1XOYL]X+[>_@+[<Y^S^)]M-ZVHUGV6LO:<OH>M0S<#]D<
MG5ZWB>R[1ZK#ZAZGX]]CHU=W(WOW:<^Y'NU:I_:/>WOCIS^2^P?]_P#N-B[_
M`&O"U-@[GSYT>3Y:Y=@O[*]\>M=LX9J[+93_`.D_T*K1HS[B]-3N-X'9[[K^
MQ/-1^[?VI^F?\>U;#<)V.[VKL7,V;YN;EX_'5W[R.U.^SK/:<#::_P!^VGJ^
MA]Q3XT^^+V%>[ORO52]G_`]]/'7L;ZA^F?/\.ST'K$3-K2_ZX9J&;W?J]O-M
MM3=?/G['D:_K>AR50C.7<W1MWB\+]6/<_P`+O&/%GC+_`(<?K+[.]6;!9>QP
MK/LW=75VB=?['CY+5UC=GM/O'V77L*VO6>IR>J?G?\']ITU:!ZIW/K7=WNU#
M=TNZ?LMMW9_EW]"^K<&UX;V*-75&KJYN#DXN2O(L_M.;MMNO:[;7.U^T]/UK
MT+JO=V--_=GW`=6?T#Y7Z;I]^7_DC\_]>[-M6V=CA^KU)[-X6\_J_#7>9G:&
M^>V_6_"=;-FGYOM^+[/3IX6'Y7'GA;^&3F[OSW'\V!_%#^E/_7]5]8;/KSL:
MG9[F?-][UO5^6A,79XQU[]>(>QVW]NZM_>OI=#55](GN^:U/%[PGIGO;^\)W
M:R1[2_QJ_@#YWU[M!PWJ.*;39C:Z^97]'Z'+I5>^\+]<N[/L[K[O974-JQJ_
MG#\>Y/9JGC+GM_K"=V?=4QQ\KYO`G-/>SXG^WU/AVF2\^\V;JZ?ZM>?W9JJ6
M[W5?W=MMV](_ZZ'LO=KWJ&-9_O?P/B-[.P1X:^[MWV/^(;_)_P##7U7F[#\5
M[13K9FM79ZW]H]7T>2K3W:_L\E=4VD_K':&Q_P"P?;?C'KVJXV1OH6LWV#X\
MZ<OI/P>Z6FSVQ]<_,?$Y6Q63JXOFVS6?-F:SUSO`]IW9;7LK$LW\[B.IR>ER
MWH-'6C]_S2UX>]T\>>,_<;Q9F_H_V-^N?F^#:M;T]L0=743K9M<^3CKT/^[;
M^R???K/6)'5-OU5&?U_P7+1S=5'B/IA\:^_\UX%=X?HL+WQ_I;^O?F>#:U8I
MUG#=MKJV>MF&?U/2Y+5YCW`[%WY[+ZHWU[99W-E_>?P'K7J,-"?=7$OBUX>Y
M*\7_`#?!TY^"_P#0;]1?%W[1L$V<3:[)>O\`ZG9_9>C1[O8Z[O%V=UV-U/\`
0]EUW^_\`X>B2;6*N(U__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g96979g88r93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96979g88r93.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0Z\4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````\````*4````&`&<`.``X
M`'(`.0`S`````0`````````````````````````!``````````````"E````
M\``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#!\````!````30```'``
M``#H``!E@```#`,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`$T#`2(``A$!`Q$!_]T`!``%_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P"7^-;_`,4&'_X3_P#1CEQB[/\`QK@_M["/8XA`^5CO_)+C$E*22222
MI))))2DEL]!^J?5.MAM[(QL$DC[59J71H[[/3]*W_C'>G3_QB[G`^I/U<P@"
M<49=@_PF4?5)_P"MF,=O]BE9W.?%^5Y:1@2<F0;PQ>K@/^LE\L?^FOCBE+78
M>+Y4;:AH7M'S"(RZK[/<=[8W5:R/"]>S,Z=T]@VLQ:6-\&UL`_ZE2&!@ZG[-
M3)B3Z;9TW?R52C_QCQDU]WEL3\X_1'%^XO\`8/</_]`G^-C_`);P/_"K_P#S
MX%Q2[7_&Q_RW@?\`A5__`)\"XI)*DDDDE*6E]7>B/ZYU-N')9CL'JY=@Y%8.
MWTV?\+>[]&S_`*Y;_@UFKTSZA]*;@]#9E.:1D=1B^PD00SC&K_J^E^E_KW*A
M\5YP\KRLIQ-9)GV\?A*7Z?\`@178X\4JZ=7H:JJZ:F4U-#*ZVAE;!PUK1M8U
MO]5JDDDN)WW;BD_8_+^*9/V/R_BG0^;_``9_]"2"_P#_T2?XV/\`EO`_\*O_
M`//@7%+M?\;'_+>!_P"%7_\`GP+BDDJ223$@`DF`-24E.C]7^CGK75J<`SZ!
MFS*<.U+/IC_KKG,H_P"N+UX`-`:T!K0(`&@`'8+F_J)T8]/Z3]KOKV9>>18Z
M?I-J_P"TU3OW?:?6<W]^U=*N.^-<Y]XYDPB;QX+A'M*?^5G_`-S_`(#9Q0X8
MWU*DDDEELJD_8_+^*9/V/R_BG0^;_!G_`-"2"__2)_C8_P"6\#_PJ_\`\^!<
M4N[_`,:6%G9'6,&S'QKKZVXSFN?56][039.USJVN]RX^OH_6;3%?3LIQ_P")
ML`_SGM:U,.3'&^*<16]R`31[-1=%]2OJ\.K9YS,EF[I^$X%S7"6VW<LI_==7
M3_.W_P#6JO\`2*WT+_%_FY%C;^M#[-C#7[*QP-S_`.3:^O<W'K_XNSU_^)7?
M4448U+,?'K;534-M=;!#6@=FM"Q?BGQG'&$L/+2X\DAPRRP/HQCKP2_3G_=^
M1EQXB3<MNR1)))<NV5))))*4G['Y?Q3)^Q^7\4Z'S?X,_P#H207_T_1\XGU&
M_P!7^*K25I7MQ@UUV1M:RMI+GO,!K1[G.<X_1:U+[+C_`+@7.\[\#YC/S.3-
M&>,1R&P)&7%MP_N,\,T8Q`(.CFI*QFY?0^GEHS\G'Q#9.SU[&U[HYV^JYNY&
MI9@Y%3;J-EM3Q+;&$.:1_)<T[57_`.3O-?YS%]L_^\7>_'L6BDM`48KBX-:T
MEIAP'8P'0[^RY!NNZ102V^ZFIS='![VM(^.YR7_)WFO\YB^V?_>*]^/8M5)7
MZJL*ZL64[+*W:M>P[FGX.:AFWI(M-)MI%H<&&O>W=O/T:]N[=O=/T4O^3O-?
MYS%]L_\`O%>_'L6HG['Y?Q5^RG#K:'6!C&DM:"XP-SB*ZVZ_G/>YK&*7V7'_
M`'`C'_B]S0-^YBVD-Y_I1X?W%>_'L7__U.V^N==N;TK]B8[MM_5R^AKN2UK*
M[<NUVW]U[<?[-_7R&(`^MHK^H;?K/`LL&(UY8?HF_2AU9C\S[7[$3(Q7=9^L
M>0UN3D8M?2*&4MLQB&%UV5^LY5;WN;9O]/&HZ<__`*^N?JZ/?D_5_P"M/U,J
M<ZR[!N]7"#B)=7?MZEB5EVC??D5VL>])3U/U<Z+7@X3<G)/VKJF<T6]0S;`#
M98]P#C7NCV8M/\UC8U?Z&FI'Z5T?"Z)]N=B[*,7*O.6:FM#&5N-=5-VW7;L?
MZ'K?R$/ZK]7IZQT/%RZS%@8*LFKAU=]8#,BBQA]U;F6?O_X/WJI]8>IU96+D
M]&Q]_K9-]/3++&C0'*'J98J=/\]B],];*_X/]$DII?5'-?\`M?,IO>2_K.-3
MURJIP@UB\OQ7T?RO0HHP*_Z^]-?T[I]W^,L&W%IL+^CNM>7UM=+QD5TMM=N'
M\YZ/Z+?_`*+]&A]3Z>[H'UAZ'U5N5D9-5]SNF9'VAX?#,AN[%:W:RO:QN54Q
M7'D#_&74"0"[HKPT>)^U,.B2FK]9L&GZLNI^LW16-Q!5=77U/%J&RG(IM>VG
M?;2S]&W*ILMW59.S?_I?51L_"PS_`(Q.EW&BLVG"R7FPL;NW,=4*W[H^FQKW
M['*?UZ)SL3%^KF/^DR^JY%.Y@Y9CTV,R<G+?^[55Z+6?U[/T:GG_`/B_Z5_X
M0RO^KH24B^OUF39T_P"QX;MF3379U4.&OMZ>:KVLV_O6Y-N.MO\`;&-^P_VW
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M#;==CV68[K`/H^O]DLI]9S?W[4%GU4Z!6*/3Q!6<9[K:7,?8UPL?'JW^HRP/
M??9MVOOL_2[/T?T%F=(S<_-=AT7=2MJ]-_4/5$8_J/;BY=5.+5E.]*YG]$/Z
M1^-Z7K,_3>I_A%FLZIUL_5_]H.ZM:<G]CCJ6W9C_`,^P$^GM]#^8M?\`H;JO
MYS_A*[$E/7=4Z)TOK#&5]2H&376265N<X-!/Y_IL<UCGM_,?^8JMOU2Z!=E-
MS+,9SLM@`9DFV[UFAHVM#,CU?69[?Y:P^I_6/J&-U#,^RY3K:64W`CT6[*35
M?ATOOHH]^7>_!P\O)RLA]OZ#,].O[-7Z-:LV=0R3U%N#B]8:V@5,R,;+R`RP
M7O=<]N50Q]3<>G);BT5TU>A4_P!7_*'J>I^BI24[^#T?IO3WVVXE`9=>0;KW
M$OM?'T?5R+C9=8UOYNZQ4G=(^KN9UJZ\L]3JV*UCK+!9:+:VVA[:FL>VQOI5
MV-9;^BJ]BQ\CK>><?97G.]5W3.IV/:!5ZC<C%LH90Z!5O;?6RS(8ZK;L]G\S
M^C1,SJ^;C=2MQ!G/MP7?L]C\PMK)I9?]M];(]2BNNIOVE]&)1ZUC?2H^T>JD
MIW,;`Z5T'$R+L>MU&.T.OO`-EGT07VVBJ;7.M=^?Z3/5N_EK/'U>^J@Q'=8&
M,0QS!FNR!9=ZAVM=:S(<[U/6=>RNRS99_/?I'K.S^IW!YQJNI69E#6WX]SGM
MI8PM^QVY5?JEK677Y/JLKL9FXU=.!Z/ZM_2/553[;U`8'V-V0W[([IL,8',+
M2&X,VX=C-OK5Y_VFRG-IN]3T+L'UZ_T;Z/TB4__9`#A"24T$(0``````50``
M``$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D
M`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&
M```````'``@``0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#
M`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`#P`*4#`1$``A$!
M`Q$!_]T`!``5_\0`T``!``("`@,!`0````````````D*!@@'"P($!0,!`0$`
M`@("`P$``````````````0(#!P4(!@D*!!````8#``$"`0<)!`@%!0```@,$
M!08'``$("1$2$R$4M787.0HB4Y34%18VMG@Q-[<803)B(]57=Y=1LR0E=:?7
M6(@9$0`"`0(#`P0-"@(&!@L!`````0(#!!$%!B$Q!T%1$@AA(C*2TA-35'24
MU!<9<4*S%!6U-G8X"8%2L6)R@K(CD<%#T[17H=&B<Z,D)56EU188_]H`#`,!
M``(1`Q$`/P"V5YCONP>T?^C3G]+L^0]Q:/=(ZN+*F88`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`W)@_W?'3W]9/"7^"7D7R2.5'_T+97F.^[![1_Z-.?TNSY
M#W%H]TCJXLJ9A@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#<F#_=\=/?UD\)?
MX)>1?)(Y4?_1ME>8[[L'M'_HTY_2[/D/<6CW2.KBRIF&`,`8`P!@#`&`,`8`
MP!@#`/Z$(AB"$(=B$+>@A"'6]B$+>_300ZUZ[WO>]_)K(;44Y2>$4"3KG'Q!
M=S](IVYZ:JMW5T+<=%FD32YU2B"H34INO>4K11PQ$OG;FC4DZ]Y*A.TF)30[
M#O1OM%H6=+>+_P"X!U9.#U6[RZ^UO]MZCHXJ5GE$8WLU);'"=PIPLJ<XO9.G
M4NHU8M-.&*:/+,KT3J#-%&I"S\30?SJO:+Y5'!S:YFHX/G)C*K_#<0=,2G47
M=TI*WM0/90U;15<2:(N2E#K>OCD)Y'+3Y>8NV,/K[31-2?V[W\I8O3Y?7IKG
M]XC4U:I5H\->#=A;45BHU<SNJMRY<TI6]JK10PY8JYJ8\DUR><6?"VW23O\`
M-9R?*J<5'_M2Z6/R]%?(;K1?P+>/1@)++=HG9LW&#0-"42BSWM(<=L)GOV(P
M,+*B!&MF!_(W[``U[?[-:%\N=;\[_=)ZVF:U)SL<]R7+(O'"-MEM&26S#9]<
M=U+9O6+>W?BMASU'AUIFFDIT:M3^U4:_P]$Y-_\`XI^,K_\`&G_ZR=`?_=7/
M"_B0==#_`)R__$9%_P#6'Z__`,'I3_VK_P`6M_O#\5/A.\9QZ<XDKG(]&8:6
M(`%2:X[W$H3B%KTT:2%79RI*(P&_EUHPL8/7^T.\RT?W(^N;2JTZD^+\:D(M
M-QEE.2*,NP^AET98/EZ,HOF:(>@M*--+*\'_`-[6_P!=0RYI\-G`K?2M@5HE
MJZ2`B$MM&GYT^(-V=8`SU,DKN)WBP1586O'(-K$Q2%LM!Y`,DL82C]J`B,"(
M11>P[HRG]P_K47?!7B!K.OK:S>?V&J=/V5&?V=8J,;>_L-2U[F#@J'0DYU,M
MM&I23E!4Y*+2G-/B*NAM.1S>QM%:3\1.VKS:\9/NH3MU%XXX[%4ELY<>PC__
MTK:WE_;UCGXR.U$R$GXYQ='21P&#XA1?M1M)R%U<#O<<,L&_FZ!$:9[=;]P_
M;[0ZV+>M;A[BT>Z1U:V5,PP!@#`&`,`8`P!@#`&`,`VJY(XUO+M.R"J[IB.?
M.@(_FRF7S9XTI10B!-*DPP!;G*7HE,J^`-3\$SYJC(`<N6B*'H@D>BS-@T;Q
M[ZP_#+JXZ.GJ[B+G'0E4Z4;2SI=&=Y?58I-T[:BY1Z2CC'QE6<H4:*E'QM2+
MG!2YC)<CS#/KI6MC2Q2[J;V0@N>3_H2Q;Y%L9=,XC\3G,G&K>UOX6)';=U$:
M)4+;:G#2D4J6Q>7KUU^X$</&N;(.F($(7L/)$<Z#T+>C5A@/86#YQ^LIU[N-
M'6(N[[*GFE3(.&\L8PRNRJRC&I!^?7$5"I>R>S&$U"VBTG"WC+I2EO?(-&Y3
MD<85/%JM?\M2:W/^I':H?*L9<\F2AYTF/+1@#`&`,`R)-_"3W]8HO]&3#-XY
M!^FSBS^>-)_=>M#AJ_X@RST.Z^DM#__3M^>5/[MSM_\`IHMC^5'#(>XM'ND=
M5AE3,,`8`P!@#`&`,`8`P!@&S_('*-D=EWC&*5K=/\$YR'MSEDH4D&'-$&A:
M$].!\E;O[!`T(I&!0`I,1[P"6+3B4X!!$;K>M*=8'CKH[J[<,\[XCZPJ]*G1
M7B[6VC)*K>WDXR=&UI8XX.;BY5)X-4J,*E62:@T^6R3)[K/<PHV%JMKVRER0
MBM\G\G(N5M+E.P1Y=Y=J3D.I&*GJ>8M-C&V:TK>7E7HDZ1S.1G$E%N4KE;D6
M43MQ>7'9(=?($!"8@!:=.640466'Y0^-O&W7O'[7N9\0>(.9^.S.MVE&C#%6
M]I;IMT[6UIMOQ=&GB^5SJ3<JM64ZLYSEV3RC*++);*G8V-/"FMK;[J4N64GR
MM_Z$MBP22-B<U&<F,`8`P!@#`,B3?PD]_6*+_1DPS>.0?ILXL_GC2?W7K0X:
MO^(,L]#NOI+0_]2WYY4_NW.W_P"FBV/Y4<,A[BT>Z1U6&5,PP!@#`&`,`8`P
M!@#`&`7V/$'Q$FY!YD9WF5,GS&[[I2MDULHU8G"6Z,"`TDP^(5^+W!T<F!&6
MI;LU82+\K3JK5:WO80%Z#\M/[@'65K=8#C1F&79'F7C>&FG*E2SRY0EC2KS3
M2N[Y<DG<58=&E-;':TJ+24I3Q[%:*R!9)E,)UJ>&85TI5,=Z7S8?W4]J_F;[
M!+#G1(\R&`,`8`P!@#`,B3?PD]_6*+_1DPS>.0?ILXL_GC2?W7K0X:O^(,L]
M#NOI+0__U;?GE3^[<[?_`*:+8_E1PR'N+1[I'5894S#`&`,`8`P!@#`&`,`E
M/\0/(8NL.O(L*0MNUE5TQM%:-C".*V-"X":5P-PZ('[%K91FY1)2B_C$"]/C
M-B1;Z?*'.CW[@/']<">`.>1RF\\7KC4?3RW+\'A.GXV#^MW4>5?5K=RZ$UW%
MS5M\=DCR_1.2_;.=4?&PQLZ&%2?,\'VL?[TMZY8J1?JSY73L:,`8`P!@#`&`
M,`R)-_"3W]8HO]&3#-XY!^FSBS^>-)_=>M#AJ_X@RST.Z^DM#__6M^>5/[MS
MM_\`IHMC^5'#(>XM'ND=5AE3,,`8`P!@#`&`,`8`P"^EX:.3-<P<=QAXD#>8
MCLR^-HK5FP510BEC8UN2(((#%S0#]AI6F>+F@5'%&`":0X.*LL7R!#Z?+=^X
MEQX]]?6$SK+\JNU4T9I?IY99]%XPJ5*<\;ZY36*?C;E.G"46XSH6]"2VMX]B
M=#9-]DY'1G4CA=W&%2?.DUVD?X1VM<DI21+/G0T\S&`,`8`P!@#`&`9$F_A)
M[^L47^C)AF\<@_39Q9_/&D_NO6APU?\`$&6>AW7TEH?_U[?GE3^[<[?_`*:+
M8_E1PR'N+1[I'5894S#`&`,`8`P!@#`&`2"^,/E'_-_U_7->.[=^T*\BYHK*
MM8`_D3&02)*T)BAG4[]NQ"*E;XL0M`M`]#-%KA##L/LV+75#KJ<=?_Y_ZOVK
M]6V%WXK5M[%9?EC7=*]NH34:L>S:T85KI-XQ<J,8M/I)/R72>3_;>=VMM..-
MM#MZG]B+6S^\VH_Q.PR"$(`A"$.@A#K00A#K6@A#K7IH(=:^36M:_LUGR6-N
M3<I/%L[+GED`8`P!@#`&`,`8!D2;^$GOZQ1?Z,F&;QR#]-G%G\\:3^Z]:'#5
M_P`099Z'=?26A__0M^>5/[MSM_\`IHMC^5'#(>XM'ND=5AE3,,`8`P!@#`&`
M,`8!=U\$O)(Z(Y9-N>5-0$EA=(*$$J($H(V!>UU8V%'E0%OWLSW?"`_?.U3U
MO9>PZ/3+TNC-;$2'V_-9^Y_QZCQ0XX0X=9%?.II/1T)VTNC+&%3,ZC3OJFS>
MZ'0I6>$L7"I0KN#Z-1X[\X>9+]G90[ZM#"YNFI=E4UW"_CBY=E...XG$SUGF
MP!@#`&`,`8`P!@#`,B3?PD]_6*+_`$9,,WCD'Z;.+/YXTG]UZT.&K_B#+/0[
MKZ2T/__1M^>5/[MSM_\`IHMC^5'#(>XM'ND=5AE3,,`8`P!@#`&`,`W=\>'*
M*[LCJNN:B&G4BA9*S<RM-P3_`!`?LVMXR>F4OX-J"ORTBE_..3M"4W6M_#6.
M!0MZ]H1>G6OK;<=;7J\<#-7Z_C5@M1RI_5,LA+!^,S"YC*-!]%[)1H)3NJL=
MG2I4)Q3Q:.?TSDTL\SBULL'XC'I5'S0CO^3'9%=F2.Q0;V]"TH$+4UHTS>V-
MB-,WMS>B)+3(T*%$2!,D1I$Y00%$)DR<L("P!UH(`AUK6O36?(Q=W=U?W5S?
M7MQ.M>UJDJE2<VY3G.;<ISE)XN4I2;<FWBVVV=FXQC",80BE!+!);DEN2/<S
M\Y88`P!@#`&`,`8`P#(DW\)/?UBB_P!&3#-XY!^FSBS^>-)_=>M#AJ_X@RST
M.Z^DM#__TK?GE3^[<[?_`*:+8_E1PR'N+1[I'5894S#`&`,`8`P!@#`+S_A1
MXI%R]S,394T:OFEO]#)V>8OA2DO6EL9@11!RB`106A>IB54<@<3'1>#T+,"I
M7!3G!V)&#>OF0_<AZR$>-G&>IHW3E]XSA_I*=6THN+[2XOG)1OKK9LE%3IQM
MJ$NVBZ=&56FTKB2.P6@\A^R,J5U7AA>W*4GSQA\R/^A])]EX/N29K/76>=#`
M&`,`8`P!@#`&`,`R)-_"3W]8HO\`1DPS>.0?ILXL_GC2?W7K0X:O^(,L]#NO
MI+0__].WYY4_NW.W_P"FBV/Y4<,A[BT>Z1U6&5,PP!@#`&`,`8!+[X<^$Q=>
M=%)IE.F4:NB*05MLHFWSQ/H39,)1HW:F(5Y_ORC"%R=P5IMK'4KVC!^RTPR3
M-EB5D"WZ_P#]PKK/QX`\(JVG=,9DJ?%#4M.I;6?0E_F6EMAT;J_V-2A*G&7B
M;66*?UFI&I!35O52\VT/I[[:S-5[BGCEUNU*6.Z4OFP[.+VR7\JP>'21>\SY
M?#L,,`8`P!@#`&`,`8`P!@&1)OX2>_K%%_HR89O'(/TV<6?SQI/[KUH<-7_$
M&6>AW7TEH?_4M^>5/[MSM_\`IHMC^5'#(>XM'ND=5AE3,,`8`P!@#`,_JNL)
MM=-C0RJ:X9%$AF\]?T$;CC2G^3XZ]>;H'QE1^];+1-J`C0U"M29[24J4HPXP
M02P"%KQ77&M=-\.=(:BUUJ_,H6FFLJM)W%Q5E\V$%CA%;YU)RPITJ<<9U:DH
M4X)RDD_TV=I<7]U0L[6FY7%22C%=E_T);V]R6+>P[%'C'E6%\;<^0>D(>!,J
M4LZ,+G-Y.2F^;*)K/G,D@<FE"H(Q#/"6K5%!)1E&#&)*WD)T_NWHK6]_(QUB
M^.6H^L/Q8U+Q+U!*<*-Q4\79VSETHV=C3<E;6T<,(XQBW.K**BJM>=6K@G-H
M[-Y%D]#(\MM\OH8-Q6,Y?SS?=2_CN7-%)<AM3FC3F!@#`&`,`8`P!@#`&`,`
MR)-_"3W]8HO]&3#-XY!^FSBS^>-)_=>M#AJ_X@RST.Z^DM#_U;?GE3^[<[?_
M`*:+8_E1PR'N+1[I'5894S#`&`,`8!["1(J7JDR%"F4+5JU02D1HTA)BE4K5
M*3`DITR9.2$9QZ@\X>@@`'6Q"%O6M:WO>8J]>A:T*UU=5H4[:G!RG.348QC%
M8RE*3P48Q2;;;226+V$QBY-1BFY-X)+E+KGAR\8QO*43U?\`=C1HOH6P&3YL
MUQQ:27LVH8:X^PX;.9^49[)K(2@EC=!_DC1$^B(.@BTJV=\WG[A?72I\=<^?
M"KAM?X\)LJN>E5N(-X9K=T\4JJW8V=!N2MEM5:>-R\5XA4]\Z'TF\GH_:5_#
M_P!3JQV1?^SB^3^W+YW,NUY\9U<]8AL(8`P!@#`&`,`8`P!@#`&`9$F_A)[^
ML47^C)AF\<@_39Q9_/&D_NO6APU?\099Z'=?26A__]:WYY4_NW.W_P"FBV/Y
M4<,A[BT>Z1U6&5,PP!@#`.0*OJFR+JFK-7-3PN0SZ;OY^B6N.QIO.<%QNM""
M$Y6HV#6B&]K1!'H:E8I&4E2E:V8<8`&MBUXIK;7.C^'&F\QU?KO4=IE6FK6.
M-2XN*BIP6_"$<>VJ5)X84Z5-2JU)80IPE)I/]-I9W5_<4[6SH2J7$MT8K%_+
MV$N5O!+>V7*/&3X<8?R@8RW7?G[%L+H@`"5[`VIO_<(54!PR][#^Q-GE@!(I
MN3HST-=1@^`C,U[4(?4&UA_SP==#]PS4''6&8\-^%?UG*>$C;A7J2_R[S-4G
M_MNBV[>S>':VJETZL7TKIX2^KTMY:4T/0R9T[_,>C5S/>EOC3^3^:?\`6W+Y
MO\SG1SUC&P1@#`&`,`8`P!@#`&`,`8`P#(DW\)/?UBB_T9,,WCD'Z;.+/YXT
MG]UZT.&K_B#+/0[KZ2T/_]>XAY.61ZDOCS[-8(ZT.C^_/'.EHM[0R,J!6ZN[
MHO51A<4F0MS:A*/6+EB@P6@@**`(8Q;]-:WO/PYEF679-E]YFN;YA0M<KMZ<
MJE6M6G&E2I0BL93J5)N,(0BMLI2:26ULR4:<ZM6%.E!RJ2>"26+;YDEM;.K^
M<.=^@&A1I*ZT9<38JV6$W29PK*:HE&RA[$$!NB5+(49LL6P;UH7IZ;WK?_AG
MA%IQ<X4W]+Q]CQ.T]6H8X=*GF-G..*WK&-9K%8K9V3DI99F4'A/+ZZ?9IR7^
MH]'["[N_Y.6I_P!O9;_PC/U>\[AK_P`PLC]?M?\`>E?L^_\`,:W>2_ZCGVN/
M'1W1:ZTE%#N5[FW\<>P%.$JAZZO&$8M#V6+7[RV%J+1[7PS-;T+U5:]F];]?
M3-5ZPZW?5CT+;5+G4/''3O:K%T[:[A?UTL,5_P"7L/K-?:MJ_P`O;R8G(VNF
M-0WDE&AD]?;RRBX+OI]&/_23!\V?AU;-?E2%[ZHM9D@+%ZEGJ(-5@PRJ9JBO
MR?B(E\K=41$4CBD._7?Q$I#Z7O6M:^3>][#Z^N,?[NFB\KH766\#M"W.:YGM
M4;W,U]6M(ODG"UI3E=7$=W:U)V4D\=Z6WS?*N&-W4<:F<7D:=/\`DI]M+Y')
MKHQ_@IEE'FKD3GKD>)BB5$5PS0\E660%^D(@C=)G*CB/40#Y/+''9[T[:`:,
M8RDXC0HTHC!:3DE!W[<]./&3C]Q9X^9ZL^XH:PN,PJ4W+Q%#93M+92WQMK6G
MT:-+%)*4U%U:BC%U:E22Q-IY5DN69+1\3EUK&">^6^4O[4GM?R;ER)&RF:;.
M5&`,`8`P!@#`&`,`8`P!@#`&`9$F_A)[^L47^C)AF\<@_39Q9_/&D_NO6APU
M?\099Z'=?26A_]"^;.OX.DW_`,*O_P#('G7+K??I<X^_E7,/^'F<_I;\1Y)Z
M33_Q(T8SY!CM*,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`9$F_A)[^L47^C)
MAF\<@_39Q9_/&D_NO6APU?\`$&6>AW7TEH?_T;YLZ_@Z3?\`PJ__`,@>=<NM
M]^ESC[^5<P_X>9S^EOQ'DGI-/_$C1C/D&.THP!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8!D2;^$GOZQ1?Z,F&;QR#]-G%G\\:3^Z]:'#5_P`099Z'=?26A__2
MOK2QK5/4<=VI%LH*I<D$03LX8BRM#$(&_P`L80C$$/IK?^C>:1ZR/#[4'%;@
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M^TCCC4G0E'!=/=A3EC_#GV?_T[_&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8!__U+_&`0B^>WN:Q.(N+TBVEY*GBMO7;/4]5QY^+3F'/\8C"B,R)ZF<
MOBQ^E*<EK?FHEO1HTZT03S$9SF`TDO1H0'DPRT5BS?7Q\WR;TYQ+S#>2U>)T
M?)W3\2.EZ\1GQ1*9ZPHM1:P1B,]=[$+4W8W#6_7\KY/E^7UR2&L&T;BX((:O
M(UY7T_+%@0KDSF:N0]*=T6TH;FV'5,B6"*C\%%("M"8'NR5B8Y,87M<2/YX4
MVZ4H/:UEF+EJQO1_!//C$LHX[7N,*B'CU\C=TM6ICV!Y2+MKR9OJ<:K=5\:M
M\:JF"UYM4,8@,*:8::Q.\UT@1F:+VI/1$*`':W_ZI5[-*#&WG&,>2)I9W92G
MEP\<-;/G3G,7D&M;I2HX'K3Q:==7Y'(E.YI&XR%002=(TJYZ:7E-)HPB";[G
M7Y@%C7-B<.U(/C$Z/,2MJ)71>QHL'<=V\\W_`,F<SW?)AM8I5;-#5-8,NTQH
MU#>S$R^509C>)8E:4*L]6H2-R21*U)1)8SCM@+!K7Q!_Z^Y*O8VCZ/5=UI^<
M.:+[OH_;9LVHZDGL];$SP$\;8Y/T=C;@OCC*K*3*D*D\#Z_E)D>BRSR3#!'Z
M"$P`MZ%H$L6D0\_A\^];4[>H_HTV^)J=-+<@M]K)&J.,V62F9*_MAF)=H@P,
MS:#8MM4<:9'&I`G;T^M[+)2E`*#O?P][R$6FL&L-Q8$R2A4-\V/7WEL\=UE1
M&207L"'*:1O25VFLK1G8J`J`B1UZW1US97!!`)4?-XA.AR/3-'Y4D(2O)*DL
MYR,2J35"=-O90!P\3)%1?)M)**^Y*\S,J@$5E$D\RC/&I)((VU/BV--7`'-\
MG:6I8YMQ"[3:5)U!L:4N)2<1^BQ*/V83Z^FQ:+WKTUC;SE<8_P`IJ5T!UOYK
M/%J`BS.E6>E.].6DK@A12BS(+&"ZLG,:)6*"D2(R2IXDSMS;!3G%3O0`JS&)
M]9]'G%D;4E'&E%[;42E&6[8R;WB+N*B.^Z50751+TK4-X%8628Q!](+03"O9
M:6C3+E<8E#>4:H3Z4%IU8#"%28T]$L)%H9)H_0>@25::>#-5/*RT]VPBEK2Z
M<Y"['54JWT72[W-9'2:NBJ9L1DG`(*)_E<NDQ,ZG<7D$HC3R*'B^&!,`M2WB
M_99?H62,\\_(9,<,<&B.?PB75Y._('&W?I*Z.\3DU15E=:>O7"HFWG'G8*NT
M!L,;B\RE+8[3-G@D;>X8TJ&V8-Z<LY``Q6/8SM@,)$6'8BQ)DHK8D6A<DH5Z
M_P`0[Y`+:XNYVK"$4',@0.TN@I3(VHZ6-X#/WOC=?0IM;5<G<8<N+5E!87Q8
M\2!K1Z7")/&4E//^!\)1\,\J&7@L7MW$U'-=PMG07/=)7BSF%#0VS5D%GX0%
M>FM)5,GCC<ZN#>8'6M?#4-C@I-3F@]-;`:4(._EUDE6L'@<V8(/_U;_&`5LO
M(;1@/)1W5<O-I:3]L,/%WCVM"0,!(0[4_,>M>FT91=8)U"+X6BA@2PZ+H'(L
M8C!&^\'L*"6(7Q@P73P6/.S'OPMU\!G?&%JT4N5B/>*"N`YQ0)_?K84,%MYM
M&_,96B]BV,&SIK'9*9O?IH(O=KT^70MX0FMN)8)Z)N5CYVH6Y+WDA7SEEJ"L
MYI8BU!HT)!KK^ZC`N>$[*F,'^2%:]*TI:0C7^DXX.O\`3DE4L7@5;OPW%9/W
M1]R]A>2J\3`3&TY!-C*[B\D7D!.TUR:4I`3.U%C04IT?^R1IF!U8&MOTG$#:
M-I/4)`_[DWVY"YR\]B21;VR3&?`ED78YO%I+"Y.@)=8U+V!YB\A:U(`F)W)C
M?VY2U.R`\`]"`,E8@5F%BUO6];"+?K@'#?*5#%<N\XTYSR1+ET[2T_"&N#(9
M:Y-A#.N>6]FT82WG*&Q,K7D(A$(MEDZ`$XS7M+UOU^7!+>+;([_,JL'9E><O
M<.MIYVW+N+JVJZZE:-+LX"PND*[?$5H7`_$#(T$[8&-*P-FC@!&5LPE2+6QZ
M![M;ADQY7S$-/B\)3\->?#L?C0A*FCT#N(%B$U_&TQ`$"%$G1Z2]`U*E0IR=
M%)=)F6HW5S2%```(?0S7L]NM;!LMY:6V*9<IR3&5#/Q9G]WO$_USO#Z$K3(9
MDAO9;`KG^[V!_4R+_0B')*/>S[$EC;!,HZ^Q&5LS=(HQ)V=RC\B8'A(2O:GI
MD>$9R!T:G)$H",A6A7HE`RC2QZV$8!;UO^W!!1=X8<7SQ,>=N8\?IGASU2=Q
MV$@IK2!Q.%['>-V:B32SG!X.,4:,*<I%'G>4MK48L!L(A;6.!8?;LT965W,R
MOMHX\I;T\B_W?'=O]&W3W^"4XRQC6]?*0V?A7?N^+B_K)L+_``2YYR$6GO++
MF24*H/DDHT/D6Z"\GQQ:0;TR>/;B.(P2K2B-&&)C^@)`Y!Z6E;DQ'A-&$V3%
MQ6#_`+J+2P>T(`*]%FAT+81[CG+IX*/99M_^&RO@5M>-]E@#@K">]\\6;.*Q
M&68/8UHXV\*4UE1E8=ZB%ZI``FREN3[_`"?0MMV#T]`>NR$UM)_\DH?_UK^9
MYY*8DY2I.*3ITY1AYYYY@"B2"2@;,-..-,V$!918`[$(0MZUK6O7>`5QO$_V
MKR">'M+JVZ.K.::ULCKCK*;2AHBUAWG6<)F;/1E;IR(/2;2^1N52=J?41B%I
M`O&0,Y.5H]*>4:`.@CUD(O)/8DB-GP[V=7M`><3K:@:SGT-FE(]"*;@2U:]P
M23,DGAST)@?S;DK;;1)&!8N97@;!7@WIM'M.;L.U0C`^@1`V7A;R9;8ID\GG
MN>'%C\2O7:UK4C2*3VRH&<TTO_6$W2'H&IV!X3;_`-A:TN9Y(O\`9,WA[BL>
MZ1JC^&!()*\;\B,*)*+&IZ;LX]2,LL`!J#@PZKTP3CQ!UK9IH4Z<LO0A>N]`
M`$/]FM:T6XF?=%B[)*#`&`5\+,Z4Y[<O.2G.O.]J?J"%\(<H+6B*CMFS(77I
M#E?O1IS6MD)D=43!V9T[F%-2SBF(6`3#&<0=[/?Z!'L.HY2^#Z.Q;R'KRZ='
M\ZUOY;N)^Y^>+SJ&V6EO!7"NX3J=L>)61I#]FL\-;)%^\"B%O#V%L.E=4/Y;
M:049L(S2D`Q`"+TWD/>6BGT6FB\>0>2I))4ICBE"=046>0>08`TD\DT&C"CB
M32]B`848`6A!$'>];UOUUEC$5$?Q9G]WO$_USO#Z$K3(9DAO9;`KG^[V!_4R
M+_0B')*/>S,\$%$7SF%F1[SB<V/D<+&D?E+9R?(`J4X1*3SG]OMAY;VU6!.=
MH\H1Q2=F2EA+T#V"^%KU#O>Q;W5[S+'N2WCY%_N^.[?Z-NGO\$IQEC&MZ^4A
ML_"N_=\7%_6387^"7/.0BT]Y8YF$K8X'$I3.).M`W1J&QQ[E<A<#-AT6@8XZ
MV*G=V6F;&(`-`2H$9@]^N]:]`_+O624*]GA_ZWXY8>8+*MOH+J_E6&71V3T/
M>?0UL0.Q+YJ-BD\>*F,J61F/PU^CDCE")P;FE/%(X2H2(#B=$DI7#T``(1[#
MD(O)/'!+8B.K\.Q8D3HWR'=T<=169L<QKB7?O.YU=+8Y(&^41:8E4+8KXR1M
MXB[ZVK%R)S2RNO)RH<@J2#!!4IT0=F"]P`:T1,]R9=+R3&?_U[8GF'Z$,YM\
M='2LR:U1Q$PE\-W3D`)1;%IV4RZWU1,#3G,V@ZWL;FPL[RM=@:U^5[&\7MT(
M?M#N'N+16+1Q/S_X1_'K"*-J*)V3RK6DUL9BKJ((+"ET@`\N;O))V!C1"F#R
ML5B>/9_[A(AJ3"RBM!((*$$HH("@`#I@')X[ROSY8J#J;Q1^2_@?J'GJO6ZK
M*@<5T=D4AB\:$Y::%3W5L\1);5`B`K5+A-X9'5\T;4II)/H#9FS#O;L9H][A
M[&7B^DFGO+4WDKHU=U%P#U)3\62_MY_F50/#Q"&]#\%5M_E\-&BL*#MJ(>]B
M)&-ZDL91D%&:WZ:V;H>MZ]-;RS,:>#1`3^%)OEL7U3T[S(M<2BWR,3UCO&.M
M9N];4KV29L#9!98J1;]FQ?-&)RA+1H\.Q:"$QT+V'7J,S>0B\UN9;BR3&,`P
M5LM"MWR)/L]89]#I!"8P;*D\AED>D;0_1YE5094O031$XNS0K6(DJZ)KVI4G
M<2!CT<C4)S"C0@&`0=`5V_%[PSS)WQ4]S=\=94/&+7F_7'3-SV-!CYT4Y''1
M*HFF3'0V'1%O1I').B)*:5[`X@^.$'Q5!&B`C$,)18MPB\FU@DS@;ST>*KDV
MG.$G"^>9Z#B%3S"H[(A#A+76'`=R!.U>2]:;!7%L<4)SDI1*0$RR0LJH!XBM
MFIPD&:`((#3="-$QDV\&R<7Q-WU_F2\=?*-FJ5H%SX&K6N`RL[XGO5&2RJ5*
MNM'Y6X%B$(PA:\+HH)?L(M!T,M4`P&OAC!O<HI+8V0/?BS/[O>)_KG>'T)6F
M0R\-[+8%<_W>P/ZF1?Z$0Y)1[V9G@@H_6PR?Y^OQ,;''HI[WB"\\V+7ITE="
M=?'1H&?EUB:)5-DSGLH1@2$2ZWT:B/!V'>_<<L*]?9L8O;7E,JV0+7'D7^[X
M[M_HVZ>_P2G&6,:WKY2&S\*[]WQ<7]9-A?X)<\Y"+3WFZ_G-M]ZKS@";UI"M
M[-L_K"8PCE2N6TL_91SHZ6R[?-I*AV`O>C1)W"!-CJD$+_4":J+T/UT+V#,B
M*VF80GPI>,V*0Z*QEPY+J^4.#!'F=G<)*]IWY<\2%>W-Z=*M>W-4I?#CCESJ
MI*$>;O8M^@S-ZUZ:UK6,$.E+G*YW5U1UUXH_/#QU8=,1=#65$V>*N%IS*T#5
M:C,<;)XN?Z#MQ`F+<#U)FBD+.I"^FE;&(LLU>`16P"T$)<;F73Z47SEX;+&(
M_]"0KRI>2'C_`*<Z^\<W/$9O>$27G2N^C(E>_1UC-[G\[K).H8')&EAT=42,
MH`D"L)#(-Z`YG%_$3)2G<CU.",!^BH?(9(II2>&TMAP:=0RS8A';`KR4L,VA
M$N:TSW&)7&'1(\L#ZTK`>].O;'-":<E5IS->NO4(M^T6MAWZ"UO6I,95R_%(
M3;GF2<ZUG7I]H0H'2M:V]'I2UUD6YA63C=>36)2EMD"A0SHRE![0V+%2)K6!
M4J]IR#-(]``(1AA810S)#''L$BGAS\E5$=7\O<]U8OM:,$]20RM6^!SBK'ER
M`WSI\75>T%LJF:-#:LT1^\B&21UJ(>E!S=\8I,)2<6/10B#``)E91:;?(1,=
MT\&=+^+_`+9+\H?C[A:ZP:G=7Y[D5TTG&T2Y0;%6^4>BBRF!>Q-0%BUPJ:8C
MV<X)E21,;J*.("S/@%DHT9N.R633719-ORAYG/'[U;#6I\;[\@=/30Y$2-_J
MR\)7'ZVEK(YZ),-6(6Y3)7!N89FF3Z)&8%2SJ58?F^M#."0/W%@8E7%KD-</
M)3YPN;^9ZM?X7S-9<+Z$ZIF:0R,UQ&JN=4-AQ^&OCT4-$DELP?(X)UCYAK$H
M.`-,Q%J#7-R6B))V26G$<H)-B,6]^XC=Z#ZZJ7@'PD-7#X+19'3MBQ:EU%;&
MK%"ZJ'>?P20=(K3;4N57:8M&"7QYT:H?8ZY!K:TS2@YQ-(+*`,D!HBG(62;E
MCR$]WBKFG/;SP[SU`.?+1@MF-]05%6L,G1D,>TCD>QSX^'MCS*29$W%[`O8W
M1U?URQ4(E224/WC'KT]0"UJ44ECB\3P\J\YYV8>'N@X#T1:,+K-LM^HK*AT'
M-ECF2F5/<[3Q)P=XP3&VK_>+W]X:G]*C5@3IBC#-B+#KTU[M88CCBL"NC^&\
M\E%"4E5%H<G=$VI&:M/%9!5C5`]3EQ_8\??"IBU-;#*8@G?56@-#6M;'B.I5
MJ<A2:4-6-V/V5L>RQ!#"+S3>U'&OXFWLCG/H!QYKJ&DK/C=GRFHGZX7"RS8@
MK$[,L36.P80QM;$J?""MM"U[.6,#A\=.F/-,1Z3:T=H&S2];AB":Q;)X.(O-
M9P5;7-E3.=D]'UO3]J,T#BL?LV#6>\IX2X-<T969(V/IS.H=B4#1(8^YKD@U
M2)2@,-#\U.+"<`@\)I!<XE7%XO8<=]6>:J'2IN=J!\7K%).S>LY@G/8(^X5G
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M='?.`%;`9[-@WO>B+33QQ/O=J>27C[I;RS^.>%D7O##^6^8)9*+@G]N#<Q$U
M@.YB6)PD5?)_VV>2!`XDQM]@[.G)<RA#1%*'PX&C=?#-$%CM"BU%[-I;4CDB
M89A'F&6Q5Y;)'%Y0S-<BC<A95J=R9GUA>T)#FSO+2XI##4J]L=&Y26>0<4(1
M9I0PB#O>MZWDF,IZ_BHYISY+6CGI@8[2AKCTK2\_DC%**O:',M7-H]`[.A$>
MF(7F4HT01[9DQ*B.LAJ`M:,HXXMXV:F`(L1XM0S)#';S&^&O/ARYOQFBN7[8
MX[_FX!2)<6W3.Q*=3W?11D7,8`KPL6]:5#@FI@5MW$[A,VE`U;UH1FE@@IML
M=A'0?2PY#__1O)_Y<^>_^1--?]L(1_P/!.+YSE1H9VB/MB)E86MN9&9L3@2-
MK2T(4S:V-Z4K7H6F1($91*5(G+U_J@+`$.O]&L$&%R6GZDFCH-\F-75U+'HP
MDE,-WDL)C+ZZ#3I];"G(&X.C8J5B)(#O>@!V/VAUOY-:P,3QC=.U%#74I]B%
M65Q%7L@HX@EXC<'C+&ZDDJ0;*4$E.#8UI5991Y6]A&'0]:$'?IOUU@'(^`:D
M67P/Q'<;^=*[0Y+YXF\J5#&8ND[]4<(52-Q&/?NWMT?=,P'5T]HM[V'YP:;H
M&Q"V'TV+?J)3:Y3*:AX]Y1H!=^UJ1YMHZJGK8#2QR""5?#8W)#2CMCV,D^1-
MC.0^*"?0P6M`&H$$(=^W6M!^3`;;WLY!?J4IJ5.RQ_E%25E)'UP$4)>]/T"B
MKP[+A$)RDI`ECDX-2A8I$2E(`6#8QB]I8`AU\FM:P1B9#$X%!8$G5I(-"XG"
MTB\X"E>EB<<9XZG6J"@?"+/5DLZ-&6I.++W[0B'H0M!^36_3`/[*X)!YXE2H
M9S#8I,T2%1M6B1RN/-$B2HU0BQ$B4I4[PC6$IU`B1;#L8-:%L.]Z]?3`,(+Y
MXH`DPLXFC*=*-*&$PHTNLH4`PLP`M"`86,+)H0!@%K6];UO6];U@G%\Y^BGG
MRA%B@]6KI"H52M4<:I5*E-:PP]0I4'C$:<>><:RB,...,%L0A"WL0A;WO>_7
M`Q?.82NXRX^=%G[0<^4>:W%?M28MVN7475ZM9\\.*.(-5_.5$6,.^<FDJ#`"
M,]WO$$P6M[]!;]0Q?.<T0Z!06NVD#!7\+B<%8B_A_#98='&>,-)?PBPDE>QN
M9$:%&'X9(-`#Z`^0.M:U\FL$&68!@$JJBK9TX$N\WK6`3)U3(BVY.YRJ'1V0
MN!#>2>H4E("5KNW+%)2(I2L-,"4$6@!&:,6M>HA;V!\!/SY0B0X"A+2%0IE!
M?N^&>GK6&$G`]X1`%[#2V4(P^X`MZWZ;^76]ZP3B^<_#_+GSW_R)IK_MA"/^
M!X&+YSEQ$B1MJ-(W-R1,@;T"8A$@0(B"DJ-$C2E`(2I$B4@!9"9,F(+"`LL`
M0@``.M:UK6L$''D@I:G):[JY!*JFK.3/SA\W^?O<@@D6>7=;\U2DHDOSMR<6
MI2M4_-D28LDOWC%["BP@UZ!#K6@Q/C?Y<^>_^1--?]L(1_P/!.+YS__2L1]@
M]1>0"J/(CR[RE7=H\W,=8=?#GPX1)'KG^92J65JGKI@$\NJ23(?MV84$Y6K=
M[+"4J3'LI0M&[_\`3%_#_P!Y!=)8-X&>,?=G27-_=%3\2=OM-0RR/=)M+H;S
M=TM2L>E->-[_`"1C&(I9";,K27S&?_L.1JU(B20&M;PI3%&KD`=!-TJ.&C$8
M)K%'I<`6KT7-O([Y6*OM^\'VT8'S^^<_,571Y:RLD89HDS6<V6/-DZ%K8HVE
M2MIBUI;4A+:J<C_BKW,*4HTX?K^0!RL/#".PFFR2HP!@#`&`,`8`P!@#`&`,
M`TC[VFW;<#J"*N_!540.X+>56W"FB41JPG-$U,R"K5R=\_>5]3J%TLAY7SU.
M]DM:8P85!PTR%6H4:(,^#Z@$K#E-W,$#`/R/`882<64<).:,HP!9X0`,$08(
M&P@."69H18Q%BWH6M"UL._3TW\F`0S>'>W.A;-%Y`8[T?<;Q=LQI+NVUJ0;)
M4X-C9'FT+)7+>R1TLN.11C3(V2+,ZY6B-5Z1IB]!":>(0A#,$(8H1:6&S!<A
M,]DE3__3L`>0/[YOPQ__`+1?R&CR'O1>/<R/KSVA+^\@_D7Y*Z&E%0S6@>2N
M&CI),H<MMK3-'+6NBU9(>R..Q,E=-[F\2"(PUO<8BPC-.?@(5"A.E4%EDZ-.
MWI.(V)-8[37*A">OGORM^9F(<HO=,P`UZ>^5W":VO;\9E4]U$U#15$J30]CB
M4%CKQ&4+H\2@]Z7G&KG%QVF;R&O>M(E@C]?!<K)>&$<3;3D'R.])2GG+MEPO
MRAC;5Z@X9N.34N\U_P`R,$E<B+N?42E(T18Z(,PBI-(6[3D]C.$XK`HS$R1H
M!IQ^;@#HY,4(:6*P>QGKJNLN_J(['X5K_HX-'2FJ.[$<S85D`K6OI;&9ASK8
M$3B3=*=,ATJ>YM(A6"F2B?4Q"YR-2H2CP)%I@$*#X9/QPP6#PY#CVXNN?*7)
M_(;U%QGR^R<L@(KCG5BM6KW"Q396B3!;W]YAI(7B1J4Z1V6/MD*%3HL;F]O!
M^RHVF(UM2L-.&`L!S:3A'!-GJ37L7RA-?D+Y]X1;DO)S3)IOQC'KFF$C5H)V
M[Q5-/5$=<&&QI&ZD%&HGYR9(O:D&>RXZP-1[:)>WJD9J]S!ZG%)VT81P;[)[
M-*]<>4M]ZQZ$\=DP3<H.ERUI$6.VX_U$HC\^:X"EJF3`;`)Q;IAK=R7.:2X3
MO)T2-*5IZ9$;>)&M$I.<?A$_.FT-1P3.5^+.].H7,KR*U'U57;3:M[^/APCB
MGUYIBKX<KO9AG,2F$EA+1%(08<ZN9LU>?W*'L`2"B2Q!<TY7S8)A!HS1#2V8
M;F8--^T/(51=K^/>>WFQ4NVTMW-;T#I.4\\-4$E;-;'.DFM<I.9"$+Q8;M,5
M^IM)F(M;L4A-VRM"1.>A/2E(P^\"H(G!-/G1M!(>F>B>D>H;MY:XY>ZQJR.<
MR-\6;[ZZ/M*"/-MB*LR=M"I[C]8536#//*T0.JUD:DWQGMX<G<1"([>TH40Q
M^PPP1@DDV:]7#W;U[Q?6,+K'J,5`/G4MV]$S2M*"L.)12R556N%!0R&0^62'
MH:PZMA:Z4V,M>(DH?%2%9&6DQ",]2)+H)Y:7XBXT,$]JW''M>>2+IQ;:MYT9
M%I%`NB$+1RU,K]J+IQSY6O6BX%'K+A9CFM>J5MB!O\I2'O36I9&\*AO=&EV1
M'$A4DDF[6GB-^")P6QG.%<=L]56!X9]=[QX-(CZ`:JAMJ\WQHED-F)E5K8Y6
M$KG[B]1EL88[/F>3(G#]PXK\V;U!KL?H2XL(U&A!,'L+D(P72PY#5/M3MKM<
M_P`7W"'0-5R^N()-.H))SBP6I(T[?+6M]1R"RQ)).C2P7;"])]1Z(KUC">B>
M?<H.<#&M2(E*:4:+9VG(2DNDTSGCOWJ/R2\7<@)K.D[[R.]V"_7S!JW52:KX
M!9S(AB%?S@LEO2N['&+'G4\2/<Z3R0@X&S%IVVTM(>6+YH<,L>A"$DV;:WUU
M7;SQU7&N%>3D%>DW`=52J\+EM^U6Y]D\$HRKC7LJ*1W22!1M[B+A8=D2]]4^
MJ%M$^-9"-*6%4H^,09O0`2V8O<<//%O>47FQ+/XW8E;5YV6Y3&P::KSEZQ*9
MKV7URA1J9X7.#+,G/3L3:WNQ_L\K6I"&-O.,5I5(0+A+"$I:L1JLPQN;1VK[
M!X<Y].]@1KR2V1P7U(]U-:;2MYC0]25=:-35N_UH-L:/W];J^=8M)(LY3>PP
MI6[]M*%A:90>XFGZ$C)V,TS:T)2=RAI88HT$Y7Z5<^/J#\]_2;)%D\T>ZJ\E
MG4KPQQM:>H3-J][<IDR1UH,=S4GHK_8C<Y/)2I:`D19QB0DP`#"Q"T8%SDM8
M]!=@VN,O#O!/3J/HD/:G&R[F5VY^<K\.Z,*I`HB)Q:Q8^-I2)^>5\?.Z"+=7
M2)SXZ3&C2/:81S\@61M2V*2"5BM($\,%NP>)_]28WR+="P)M\O\`XY)4%KLU
MVB'+BNX$%Y2V.U!9TACD*6V9'2&-@3[<F:*+"W_:4XL)RX39I8!(08'8A;'H
M8`QREUW+++#*\-TB9FF0,ZGYXT/K8@>&I7\$]/\`.FYS2E+4*GX"HHA21\=,
M>$7L,``P/KZ"#K>MZR2A7N\<EV0Y9Y4_*PZ%)9DFBW0SAS])*DEKQ7%CQYAE
MZ.D:ZFK7/0(%S[$6Y*2-M->_<#2DQ.)4$G>TP3P[]VH6]EY+M8FIW/W6-CU(
MP><:SN:*_F,MNN4WL_W]SZRRRH[.;FN:5J9(R(W)+$9TSM&6L#N;"8ZZGO86
M@X92M4%.5H1&RA&>USC#N<=QQ&\7]`W'J+Q$=GOD][(NMDC3W::+J&\;1JBX
MB:^B%H696\<9VRNZPKEF@[+7L>#'9*%U"XIX0S*"S$FDGSE:XFIR]E.8G#9)
M;#?^A.@:^D'G4OJ?$([*:H99/*]<TE#)'*:9MV(MKG:K/*X@Y.L+5CDT(:CF
M!U;RRCRC=N0$A`%28TG9GQ`Z")RD-=JCPLZR8SO\1+1TM"GF(XE'.01<X/4L
M+KBQ#(L@NB0V/:+FT0PV1%Q83,,2M%,&T6W`!XFHH2G0#%(1@,"!RCYC,FI*
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M,XRQY',CXL"`QB&Q2-R72IW,<W1&J*4(CDQ1!AQR("ER%FNVQY#]+WE;O-_`
M[Q$]PRL;@=U/*5I\DN=M,KE5<\BCBD0UNT.**0.T=U*(^UES&,`7NR(D+PT;
M7MH1*M:$<$12@)3D'SV;*>8_KFH.H.`X9JC$]K3PV5]#52\1U.CHJYFX]W::
M_5MLJFSJA`\05OTI:XTE>4Z4]4#8DXW(0TA0S#R3P%F1%;3PO6])-Q%Y-6[R
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MG9=P3:OY+3-F"5OG%=V3YDA,NM1!&5T-&1)4\::9*6K7LQNM*=(M&[.+`#7O
MTYPUCT5V#65#R5P=KL24PA-:5F[\.1BN!7N],IX+'W20>RB6:R&V,TDU3=2T
@_O"!G'5A[NXN"I$H^>"V%&S+5OSL*#6/Z!B\/ZQ__]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
